

Optional Customer No. Bar Code

09/831253



00140

PATENT TRADEMARK OFFICE

JC17 Rec'd PCT/PTO 07 MAY 2001

CHAPTER II

TRANSMITTAL LETTER
TO THE UNITED STATES ELECTED OFFICE (EO/US)

(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

PCT/ES99/00375	23 NOVEMBER 1999	24 NOVEMBER 1998
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
"TGF β 1-INHIBITOR PEPTIDES"		
TITLE OF INVENTION		
1.	IGNACIO JOSE EZQUERRO SAENZ	
2.	JUAN JOSE LASARTE SAGASTIBELZA	
3.	JESUS PRIETO VALTUENA	
4.	FRANCISCO BORRAS CUESTA	
APPLICANT(S)		

Box PCT
Assistant Commissioner for Patents
Washington D.C. 20231
ATTENTION: EO/US

NOTE: The completion of those filing requirements that can be made at a time later than 30 months from the priority date results from the Commissioner exercising his judgment under the authority granted under 35 USC 371(d). The filing

CERTIFICATION UNDER 37 C.F.R. 1.10*

(Express Mail label number is *mandatory*.)

(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date May 7, 2001, in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number EL728212738US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

MARIA MELIAN

(type or print name of person mailing; *per*)

Signature of person mailing paper

WARNING: Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

***WARNING:** Each paper or fee filed by "Express Mail" *must* have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will *not* be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Transmittal Letter to the United States Elected Office (EO/US)—page 1 of 8) 13-18

receipt will show the actual date of receipt of the last item completing the entry into the national phase. See 37 C.F.R. §1.491 which states: "An international application enters the national state when the applicant has filed the documents and fees required by 35 USC 371(c) within the periods set forth in § 1.494 and § 1.495."

WARNING: Where the items are those which can be submitted to complete the entry of the international application into the national phase are subsequent to 30 months from the priority date the application is still considered to be in the international state and if mailing procedures are utilized to obtain a date the express mail procedure of 37 C.F.R. §1.10 must be used (since international application papers are not covered by an ordinary certificate of mailing - See 37 C.F.R. §1.8.

NOTE: Documents and fees must be clearly identified as a submission to enter the national state under 35 USC 371 otherwise the submission will be considered as being made under 35 USC 111. 37 C.F.R. § 1.494(f).

1. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. 371:

- a. [X] This express request to immediately begin national examination procedures (35 U.S.C. 371(f)).
- b. [X] The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

2.Fees

CLAIMS FEE	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
[]*	TOTAL CLAIMS	15 - 20 =		x \$ 18.00 =	\$
	INDEPENDENT CLAIMS	2 - 3 =		x \$ 80.00 =	
	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$270.00				
BASIC FEE**	[] U.S. PTO WAS INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where an International preliminary examination fee as set forth in § 1.482 has been paid on the international application to the U.S. PTO: [] and the international preliminary examination report states that the criteria of novelty, inventive step (non-obviousness) and industrial activity, as defined in PCT Article 33(2) to (4) have been satisfied for all the claims presented in the application entering the national stage (37 CFR 1.492(a)(4)) \$100.00 [] and the above requirements are not met (37 CFR 1.492(a)(1)) \$690.00 [x] U.S. PTO WAS NOT INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where no international preliminary examination fee as set forth in § 1.482 has been paid to the U.S. PTO, and payment of an international search fee as set forth in § 1.445(a)(2) to the U.S. PTO: [] has been paid (37 CFR 1.492(a)(2)) \$710.00 [x] has not been paid (37 CFR 1.492(a)(3)) \$1,000.00 [] where a search report on the international application has been prepared by the European Patent Office or the Japanese Patent Office (37 CFR 1.492(a)(5)) \$860.00				
	Total of above Calculations				1000.00
SMALL ENTITY	Reduction by ½ for filing by small entity, if applicable. Affidavit must be filed. (note 37 CFR 1.9, 1.27, 1.28)				-500.00
	Subtotal				500.00
	Total National Fee				\$ 500.00
	Fee for recording the enclosed assignment document \$40.00 (37 CFR 1.21(h)). (See Item 13 below). See attached "ASSIGNMENT COVER SHEET".				
TOTAL	Total Fees enclosed				\$500.00

*See attached Preliminary Amendment Reducing the Number of Claims.

- i. ☒ A check in the amount of \$500.00 to cover the above fees is enclosed.
ii. ☐ Please charge Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.

****WARNING:** "To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date: * * * (2) the basic national fee (see § 1.492(a)). The 30-month time limit may not be extended." 37 C.F.R. § 1.493(b).

WARNING: If the translation of the international application and/or the oath or declaration have not been submitted by the applicant within thirty (30) months from the priority date, such requirements may be met within a time period set by the Office. 37 C.F.R. § 1.495(b)(2). The payment of the surcharge set forth in § 1.492(e) is required as a condition for accepting the oath or declaration later than thirty (30) months after the priority date. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than thirty (30) months after the priority date. Failure to comply with these requirements will result in abandonment of the application. The provisions of § 1.136 apply to the period which is set. Notice of Jan. 3, 1993, 1147 O.G. 29 to 40.

3. ☒ A copy of the International application as filed (35 U.S.C. 371(c)(2)):

NOTE: Section 1.495 (b) was amended to require that the basic national fee and a copy of the international application must be filed with the Office by 30 months from the priority date to avoid abandonment "The International Bureau normally provides the copy of the international application to the Office in accordance with PCT Article 20. At the same time, the International Bureau notifies applicant of the communication to the Office. In accordance with PCT Rule 47.1, that notice shall be accepted by all designated offices as conclusive evidence that the communication has duly taken place. Thus, if the applicant desires to enter the national stage, the applicant normally need only check to be sure the notice from the International Bureau has been received and then pay the basic national fee by 30 months from the priority date." Notice of Jan. 7, 1993, 1147 O.G. 29 to 40, at 35-36. See item 14c below.

- a. ☐ is transmitted herewith.
b. ☐ is not required, as the application was filed with the United States Receiving Office.
c. ☒ has been transmitted
i. ☒ by the International Bureau.
Date of mailing of the application (from form PCT/IB/308): 2 JUNE 2000.
ii. ☐ by applicant on _____
Date

4. ☒ A translation of the International application into the English language (35 U.S.C. 371(c)(2)):

- a. ☒ is transmitted herewith.
b. ☐ is not required as the application was filed in English.
c. ☐ was previously transmitted by applicant on _____
Date
d. ☐ will follow.

10. ☒ An oath or declaration of the inventor (35 U.S.C. 371(c)(4)) complying with 35 U.S.C. 115
- a. ☐ was previously submitted by applicant on _____ Date _____
- b. ☐ is submitted herewith, and such oath or declaration
- i. ☐ is attached to the application.
- ii. ☐ identifies the application and any amendments under PCT Article 19 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. 1.70.
- c. ☒ will follow.

Other document(s) or information included:

11. ☒ An International Search Report (PCT/ISA/210) or Declaration under PCT Article 17(2)(a):
- a. ☐ is transmitted herewith.
- b. ☒ has been transmitted by the International Bureau.
 Date of mailing (from form PCT/IB/308): 2 JUNE 2000.
- c. ☐ is not required, as the application was searched by the United States International Searching Authority.
- d. ☐ will be transmitted promptly upon request.
- e. ☐ has been submitted by applicant on _____ Date _____
12. ☐ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98:
- a. ☐ is transmitted herewith.
 Also transmitted herewith is/are:
☐ Form PTO-1449 (PTO/SB/08A and 08B).
☐ Copies of citations listed.
- b. ☐ will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).
- c. ☐ was previously submitted by applicant on _____ Date _____
13. ☐ An assignment document is transmitted herewith for recording.

A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.

14. [x] Additional documents:
- a. [] Copy of request (PCT/RO/101)
 - b. [x] International Publication No. WO 00/31135
 - i. [x] Specification, claims and drawing
 - ii. [] Front page only
 - c. [] Preliminary amendment (37 C.F.R. § 1.121)
 - d. [x] Other

28 PAGES OF DRAWINGS; FORM PCT/IPEA/401; FORM PCT/IPEA/408
FORM PCT/IPEA/409; FORM PCT/IPEA/416; REPLY TO WRITTEN
OPINION

15. [x] The above checked items are being transmitted
- a. [x] before 30 months from any claimed priority date.
 - b. [] after 30 months.
16. [] Certain requirements under 35 U.S.C. 371 were previously submitted by the applicant on _____, namely:
- _____
- _____
- _____

AUTHORIZATION TO CHARGE ADDITIONAL FEES

WARNING: *Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges if extra claims are authorized.*

NOTE: *"A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).*

NOTE: *"Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.26(a).*

[X] The Commissioner is hereby authorized to charge the following additional fees that may be required by this paper and during the entire pendency of this application to Account No. 12-0425.

[X] 37 C.F.R. 1.492(a)(1), (2), (3), and (4) (filing fees)

WARNING: *Because failure to pay the national fee within 30 months without extension (37 C.F.R. § 1.495(b)(2)) results in abandonment of the application, it would be best to always check the above box.*

[] 37 C.F.R. 1.492(b), (c) and (d) (presentation of extra claims)

NOTE: *Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must*

only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.492(d)), it might be best not to authorize the PTO to charge additional claim fees, except possible when dealing with amendments after final action.

- ☒ 37 C.F.R. 1.17 (application processing fees)
- ☒ 37 C.F.R. 1.17(a)(1)-(5)(extension fees pursuant to § 1.136(a).
- ☒ 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 C.F.R. § 1.311(b).

NOTE: 37 C.F.R. 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying . . . issue fee." From the wording of 37 C.F.R. § 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

- ☐ 37 C.F.R. § 1.492(e) and (f) (surcharge fees for filing the declaration and/or filing an English translation of an International Application later than 30 months after the priority date).

SIGNATURE OF PRACTITIONER

WILLIAM R. EVANS

(type or print name of practitioner)

Reg. No.: 25,858

Tel. No.: (212) 708-1930

P.O. Address

Customer No.: 00140

c/o Ladas & Parry
 26 West 61st Street
 New York, N.Y. 10023



JC17 Rec'd PCT/PTO 11 JUN 2001
PATENT

P E I #4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: JOSÉ EZQUERRO SAENZ, ET AL Group No.:
Serial No.: 09/831,253
Filed: MAY 7, 2001 Examiner:
For: TGFβ1-INHIBITOR PEPTIDES

Attorney Docket No.: U013446-9
Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Please amend the above identified application as follows:

IN THE SPECIFICATION

On the page after page 24 and before page 26 (copy attached), please insert page number -- 25 --.

IN THE CLAIMS


9. (Amended) Mimotopes of any of the active peptides of Claim 1, characterized in that they display an antagonistic effect similar to them, but a longer average life in the body than the latter.

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231

Date: June 6, 2001

Clifford J. Mass
(Type or print name of person mailing paper)


(Signature of person mailing paper)

10. (Amended) Method of using at least one of the active peptides of Claim 1 and/or at least one of their mimotopes for manufacturing a composition for application in liver diseases.

11. (Amended) Method of using at least one DNA that codes for at least one of the active peptides of Claim 1 for manufacturing a composition for application in liver diseases that optionally includes at least one of the mimotopes of the said active peptides.



12. (Amended) Method of using at least one recombinant expression system that codes for at least one of the active peptides of Claim 1 for manufacturing a composition for application in liver diseases that optionally includes at least one of the mimotopes for the said active peptides.

15. (Amended) Method according to Claim 11 for application to hepatic fibrosis.

REMARKS

The above amendatory action is taken for the purpose to avoid claim fees that would otherwise accrue due to the presence of multiply dependent claims.

Respectfully submitted,


WILLIAM R. EVANS
LADAS & PARRY
26 WEST 61ST STREET
NEW YORK, NEW YORK 10023
REG.NO. 25,858 (212) 708-1930


MARK-UP

9. (Amended) Mimotopes of any of the active peptides of claim [Claims] 1 [to 8] characterized in that they display an antagonistic effect similar to them, but a longer average life in the body than the latter.

10. (Amended) Method of using at least one of the active peptides of claim [Claims] 1 [to 8] and/or at least one of their mimotopes for manufacturing a composition for application in liver diseases.

11. (Amended) Method of using at least one DNA that codes for at least one of the active peptides of claim [Claims] 1 [to 8] for manufacturing a composition for application in liver diseases that optionally includes at least one of the mimotopes of the said active peptides.

12. (Amended) Method of using at least one recombinant expression system that codes for at least one of the active peptides of claim [Claims] 1 [to 8] for manufacturing a composition for application in liver diseases that optionally includes at least one of the mimotopes of the said active peptides.

15. (Amended) Method according to claim [Claims] 11 [to 14] for application to hepatic fibrosis.

Peptide	-25- Sequence
P12 ⁽¹²²⁻¹²⁵⁾	PheCysLeuGlyProCysProTyrIleTrpSerLeuAspThr
P28 ⁽¹²²⁻¹⁴⁴⁾	PheCysLeuGlyProCysProTyrIleTrpSerLeuAspThrGlnLysVal LeuAlaLeuTyr
P29 ⁽¹³¹⁻¹⁷⁵⁾	HisGluProLysGlyTyrHisAlaAsnPheCysLeuGlyProCysProTyr IleTrpSerLeuAspThr
P30	PheSerLeuGlyProCysProTyrIleTrpSerLeuAspThr
P31	PheCysLeuGlyProSerProTyrIleTrpSerLeuAspThr
P32	PheSerLeuGlyProSerProTyrIleTrpSerLeuAspThr
P33	PheCysLeuGlyProCysProTyrIleTrpSerAspAspAsp
P34	AspAspAspGlyProCysProTyrIleTrpSerLeuAspThr
P35	AspAspAspGlyProCysProTyrIleTrpSerAspAspAsp
P36	GlyProCysProTyrIleTrpSerAspAspAsp
P37	AspAspAspGlyProCysProTyrIleTrpSer
P38	AspGlyProCysProTyrIleTrpSerAsp

Fig. 6 shows the results of inhibition of TGFβ1 by
5 the peptides in Table 3.

It can be seen from Fig. 6 that peptide P29 is
active. This peptide includes the previously tested
peptide P12 and has 9 extra amino acids towards the N-
terminal end (Fig. 4). Investigations conducted by
10 Quian SW et al. (1992) Proc. Natl. Acad. Sci. 89:6290-
6294) and by Burmester JK et al. (1993) Proc. Natl.
Acad. Sci. 90:8628-8632) using chimeric recombinant
proteins identified a region of TGFβ1 that is necessary
for the activity of this cytokine (amino acids 40 to 82
15 in the sequence of mature TGFβ1). It was speculated
that peptide P29 (amino acids 34 to 56 in the sequence
of mature TGFβ1), extending over a larger region than
peptide P12 (amino acids 43 to 56), might acquire a
three-dimensional structure more like the structure of
20 the TGFβ1 in circulation. For this reason, peptide P29
was used for tests of binding to the cell receptors,
based on affinity labelling.

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ignacio Jose EZQUERRO SAENZ, et al

Serial No.: 09/831,253

Group No.:

Filed: May 7, 2001

Examiner:

For: TGF β 1-INHIBITOR PEPTIDES

Attorney Docket No.: U-013446-9

Commissioner Patents and Trademarks
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Prior to an examination of this application on the merits, please amend the application as follows:

IN THE SPECIFICATION:

Delete the pages following the Abstract containing the Sequence Listing in entirety.

Page 47, after line 25 insert the following Sequence Listing

CERTIFICATE OF MAILING (37 CFR 1.10)

I hereby certify that this paper is being deposited with the United States Postal Service on this date November 20, 2001 in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" Mailing Label Number EV011019229US addressed to the: Commissioner of Patents and Trademarks, Washington, DC 20231

JENNIFER RASHKIN

(Type or print name of person mailing paper)


(Signature of person mailing paper)

NOTE: Each paper or fee referred to as enclosed herein has the number of the "EXPRESS MAIL" mailing label placed thereon prior to mailing 37 CFR 1.16(b).

SEQUENCE LISTING

<110> EZQUERRO SAENZ, Ignacio Jose
 LASARTE SAGASTIBELZA, Juan Jose
 PRIETO VALTUENA, Jesus
 BORRAS CUESTA, Francisco

<120> TGFβb1-inhibitor peptides

<130> U-013446-9

<140> 09/831,253

<141> 2001-05-07

<150> PCT/ES99/00375

<151> 1999-11-23

<150> P9802465

<151> 1998-11-24

<160> 10

<210> SEQ ID NO: 1

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from TGFβb1, position 319-333

<400> His	Ala	Asn	Phe	Cys	Leu	Gly	Pro	Cys	Pro	Tyr	Ile	Trp	Ser	Leu
				5					10					15

<210> SEQ ID NO: 2

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from TGFβb1, position 322-335

<400> Phe	Cys	Leu	Gly	Pro	Cys	Pro	Tyr	Ile	Trp	Ser	Leu	Asp	Thr
				5					10				

<210> SEQ ID NO: 3

<211> 12

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Deduced as complementary to TGF β b1, position 731-742

<400> Thr Ser Leu Asp Ala Thr Met Ile Trp Thr Met Met
5 10

<210> SEQ ID NO: 4

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Overlapping with the extracellular region of the rat type III receptor,
position 245-259

<400> Ser Asn Pro Tyr Ser Ala Phe Gln Val Asp Ile Ile Val Asp Ile
5 10 15

<210> SEQ ID NO: 5

<211> 9

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Modification P54 deduced as complementary to TGF β b1, position 731-742

<400> Thr Ser Leu Met Ile Trp Thr Met Met
5

<210> SEQ ID NO: 6

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from the modified human type III receptor, position 729-742

<400> Thr Ser Leu Asp Ala Ser Ile Ile Trp Ala Met Met Gln Asn
5 10

<210> SEQ ID NO: 7

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from the modified human type III receptor, position 241-254

<400> Ser Asn Pro Tyr Ser Ala Phe Gln Val Asp Ile Thr Ile Asp
5 10

<210> SEQ ID NO: 8

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Position 247-261 of endoglin

<400> Glu Ala Val Leu Ile Leu Gln Gly Pro Pro Tyr Val Ser Trp Leu
5 10 15

<210> SEQ ID NO: 9

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Position 445-459 of endoglin

<400> Leu Asp Ser Leu Ser Phe Gln Leu Gly Leu Tyr Leu Ser Pro His
5 10 15

<210> SEQ ID NO: 10

<211> 23

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Modification P12, position 322-335 of TGFβ1

<400> His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly Pro Cys Pro Tyr
5 10 15


Ile Trp Ser Leu Asp Thr
20

REMARKS


The above amendatory action is taken in response to the Notification to Comply with Sequence Listing Requirements mailed 20 June and 13 September 2001. Applicants submit herewith a paper copy and a computer readable form copy of the Sequence Listing and statements that the contents of the paper and computer readable form copies are the same and include no new matter.

Applicants have now complied with the requirements in the aforementioned notification and now respectfully request an early examination of this application on the merits.

Respectfully submitted,



CLIFFORD J. MASS
LADDS & PARRY
76 WEST 61ST STREET
NEW YORK, NY 10023
REG. NO. 30,086 (212) 708-1890



SEQUENCE LISTING

<110> EZQUERRO SAENZ, Ignacio Jose
LASARTE SAGASTIBELZA, Juan Jose
PRIETO VALTUENA, Jesus
BORRAS CUESTA, Francisco

<120> TGFβb1-inhibitor peptides

<130> U-013446-9

<140> 09/831,253

<141> 2001-05-07

<150> PCT/ES99/00375

<151> 1999-11-23

<150> P9802465

<151> 1998-11-24

<160> 10

<210> SEQ ID NO: 1

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from TGFβb1, position 319-333

<400> His Ala Asn Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu
5 10 15

<210> SEQ ID NO: 2

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from TGFβb1, position 322-335

<400> Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr
5 10

<210> SEQ ID NO: 3

<211> 12

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Deduced as complementary to TGFβb1, position 731-742

<400> Thr Ser Leu Asp Ala Thr Met Ile Trp Thr Met Met
5 10

<210> SEQ ID NO: 4

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Overlapping with the extracellular region of the rat type III receptor,
position 245-259

<400> Ser Asn Pro Tyr Ser Ala Phe Gln Val Asp Ile Ile Val Asp Ile
5 10 15

<210> SEQ ID NO: 5

<211> 9

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Modification P54 deduced as complementary to TGFβb1, position 731-742

<400> Thr Ser Leu Met Ile Trp Thr Met Met
5

<210> SEQ ID NO: 6

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from the modified human type III receptor, position 729-742

<400> Thr Ser Leu Asp Ala Ser Ile Ile Trp Ala Met Met Gln Asn
5 10

<210> SEQ ID NO: 7

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from the modified human type III receptor, position 241-254

<400> Ser Asn Pro Tyr Ser Ala Phe Gln Val Asp Ile Thr Ile Asp
5 10

<210> SEQ ID NO: 8

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Position 247-261 of endoglin

<400> Glu Ala Val Leu Ile Leu Gln Gly Pro Pro Tyr Val Ser Trp Leu
5 10 15

<210> SEQ ID NO: 9

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Position 445-459 of endoglin

<400> Leu Asp Ser Leu Ser Phe Gln Leu Gly Leu Tyr Leu Ser Pro His
5 10 15

<210> SEQ ID NO: 10

<211> 23

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Modification P12, position 322-335 of TGFβb1

<400> His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly Pro Cys Pro Tyr
 5 10 15
 Ile Trp Ser Leu Asp Thr
 20

Ile Trp Ser Leu Asp Thr
20

Practitioner's Docket No. U 013446-9

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

[X] In re application of: Jesús PRIETO VALTUEÑA, et al.

Application No.: PCT/ES99/00375

Group No.:

Filed: 23 November 1999

Examiner:

For: "TGF 1-INHIBITOR PEPTIDES"

[] *Patent No.:

Issue Date:

*NOTE: Insert name(s) of inventor(s) and title also for patent Where statement is with respect to a maintenance fee payment, also insert application number and filing date, and add Box M. Fee to address.

STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(c-f) and 1.27(b-d))

With respect to the invention described in

[] the specification filed herewith.

[X] application no. PCT/ES99/00375 filed 23 November 1999

[] patent no. _____ issued _____.

I. IDENTIFICATION AND RIGHTS AS A SMALL ENTITY

I hereby state that I am

(complete either (a), (b), (c) or (d) below)

(a) Independent Inventor

[] a below named independent inventor, and that I qualify as an independent inventor, as defined in 37 CFR 1.9(c), for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office.

(b) Noninventor Supporting a Claim by Another

[] making this statement to support a claim by

for a small entity status for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code. I hereby state that I would qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code, if I had made the above identified invention.

(c) Small Business Concern

[] the owner of the small business concern identified below:

[X] an official of the small business concern empowered to act on behalf of the concern identified below:

check
one →

Name of Concern INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA, S.A.
Address of Concern Avda. Pío XII, 53 - 31008 Pamplona, Navarra, Spain
and

that the above identified small business concern qualifies as a small business concern, as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

(d) Non-Profit Organization

☐ an official empowered to act on behalf of the nonprofit organization identified below:

Name of Organization _____
Address of Organization _____

TYPE OF ORGANIZATION

- ☐ University or Other Institution of Higher Education
☐ Tax Exempt Under Internal Revenue Service Code (26 USC 501(a) and 501(c) (3))
☐ Nonprofit Scientific or Educational Under Statute of State of the United States of America
(Name of State _____)
(Citation of Statute _____)
☐ Would Qualify as Tax Exempt Under Internal Revenue Service Code (26 USC 501(a) and 501(c) (3)), if Located in the United States of America
☐ Would Qualify as Nonprofit Scientific or Educational Under Statute of State of the United States of America, if Located in the United States of America
(Name of State _____)
(Citation of Statute _____)

and that the nonprofit organization identified above qualifies as a nonprofit organization, as defined in 37 CFR 1.9(e), for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code.

II. OWNERSHIP OF INVENTION BY DECLARANT

I hereby state that rights under contract or law remain with and/or have been conveyed to the above identified

<input type="checkbox"/> person	<input checked="" type="checkbox"/> concern	<input type="checkbox"/> organization
(item (a) or (b) above)	(item (c) above)	(item (d) above)

EXCEPT, that if the rights held are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held (1) by any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, (2) any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or (3) a nonprofit organization under 37 CFR 1.9(e).

- ☒ no such person, concern, or organization
☐ person, concerns or organizations listed below*

*NOTE: Separate statements are required from each named person, concern or organization having rights to the invention as to their status as small entities. (37 CFR 1.27)

Full Name _____
Address _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

Full Name _____
Address _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

III. ACKNOWLEDGEMENT OF DUTY TO NOTIFY PTO OF STATUS CHANGE

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

IV. DECLARATION

(check the following item, if desired)

NOTE: The following verification statement need not be made in accordance with the rules published on October 10, 1997, 62 Fed. Reg. 52131, effective December 1, 1997.

NOTE: "The presentation to the Office (whether by signing, filing, submitting, or later advocating) of any paper by a party, whether a practitioner or non-practitioner, constitutes a certification under § 10.18(b) of this chapter. Violations of § 10.18(b)(2) of this chapter by a party, whether a practitioner or non-practitioner, may result in the imposition of sanctions under § 10.18(c) of this chapter. Any practitioner violating § 10.18(b) may also be subject to disciplinary action. See §§ 10.18(d) and 10.23(c)(15)." 37 CFR 1.4(d)(2).

- ☐ I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

V. SIGNATURES

(complete only (e) or (f) below)

(e)

NOTE: All inventors must sign the statement.

Name of Inventor

Date: _____

Signature of Inventor

Name of Inventor

Date: _____

Signature of Inventor

Name of Inventor

Date: _____

Signature of Inventor

(add lines for any additional inventors who must sign)

or

(f)

NOTE: The title of the person signing on behalf of a concern or nonprofit organization should be specified.

Name of Person Signing _____

Title of Person _____
(if signing on behalf of a concern or non-profit organization)

Address of Person Signing INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA, S.A.

Avda. Pío XII, 5B + 31008 Pamplona, Navarra, Spain

SIGNATURE _____

DATE April 30, 2001

D. Fernando de la Puente

"TGF β 1-INHIBITOR PEPTIDES"DESCRIPTION OF THE STATE OF THE ART

5 Cell growth is regulated by various proteins of the growth factor group (Schalch DS et al. (1979) Endocrinology 104:1143-1151). The most important growth factors involved in cell development, and able to act by autocrine and paracrine mechanisms, include the transforming growth factors (TGFs) (Braun L. et al. (1988) Cell Biol. 85:1539-1543; Lyons RM and Moses HL (1990) Eur. J. Biochem. 187:467-473).

10 The term TGF was first used for describing the activity produced by a cell line transformed with the murine sarcoma virus (deLarco JE and Todaro GJ (1978) Proc. Natl. Acad. Sci. 75:4001-4005; Mizel SB et al. (1980) Proc. Natl. Acad. Sci. 77:2205-2208). The supernatant of these cells was able to induce normal growth, in soft agar, of cells that require a solid support for growth. More specific studies demonstrated two classes of TGF, called TGF α and TGF β , which in turn comprise families of related proteins. The TGF β family consists of 5 isoforms (Brand T. and Schneider MD (1995) J. Mol. Cell Cardiol. 27:5-18) of dimeric structure (Schlunneger MP and Grutter MG (1992) Nature 358:430-434; Brand T. and Schneider MD (1995) J. Mol. Cell Cardiol. 27:5-18). Investigations of the mature proteins, purified from a single species, demonstrated a high degree of identity between their sequences (Table 1).

Table 1. Homology among different types of TGF β s. TGF β 1, TGF β 2 and TGF β 3 derived from humans, TGF β 4 derived from chicken and TGF β 5 from frog. (Roberts AB and Sporn MB, 1990).

% of	TGFβ1	TGFβ2	TGFβ3	TGFβ4	TGFβ5
TGFβ1	100				
TGFβ2	71	100			
TGFβ3	72	76	100		
TGFβ4	82	64	71	100	
TGFβ5	76	66	69	72	100

TGFβ1 is synthesized as a precursor of 390 amino acids called Pre-Pro-TGFβ1. In a first hydrolysis there is release of a hydrophobic fragment of 29 amino acids, which gives rise to Pro-TGFβ1. Then the mature TGFβ1 is released by another cut in a region that precedes the terminal amino of TGFβ1 and that consists of two arginines, giving rise to a protein of 112 amino acids with a molecular weight of 12 kDa. To produce the biologically active form, two of these monomers join together by means of disulphide bridges, yielding a dimer of 25 kDa. Alterations of this structure cause loss of biological function (Barnard JA et al. (1990) Biochim. Biophys. Acta 1032:79-87).

Various domains are known to exist within the structure of TGFβ1. One of these domains is found to be located between amino acids 40 and 82 and is involved in the binding of TGFβ1 to its cell receptors (Quian SW et al. (1992) Proc. Natl. Acad. Sci. 89:6290-6294; Burmester JK et al. (1993) Proc. Natl. Acad. Sci. 90:8628-8632).

Receptors of TGFβ1 and other binding proteins

Five types of specific receptors for TGFβ1 have been characterized (Cheifetz S et al. (1988) J. Biol. Chem. 263:17225-17228 and López Casillas F. et al. (1991) Cell 67:785-795). These receptors have different affinities for the different types of TGFβ1. Receptors

- 3 -

- of type I, II and III are the best understood so far (reviewed in Attisano L et al. (1994) Biochim. Biophys. Acta 1222:71-80; Derynck R. (1994) Trends Biochem. Sci. 19:548-553; Yingling et al. (1995) Biochim. Biophys. Acta 1242:115-136). Type IV receptors have also been described (MacKay K. and Danielpour D. (1991) J. Biol. Chem. 266:9907-9911) and type V (Ichijo H. et al. (1991) J. Biol. Chem. 266:22459-22464). It has also been reported that the transmembrane and cytoplasmic domains of endoglin (Cheifetz S et al. (1993) J. Biol. Chem. 267:19027-19030; Bellón T. et al. (1993) Eur. J. Immunol. 23:2340-2345; Yamashita et al. (1995) J. Biol. Chem. 269:1995-2001; Zhang H. et al. (1996) J. Immunol. 156:564-573) have approximately 70% similarity with the type III receptors, both human and of the rat.

- RIII would be the one with the task of binding TGF β 1 and presenting it to RII which in its turn would form a complex with RI (Yamashita et al. (1994) J. Biol. Chem. 269:20172-20178) or to complexes in which various molecules of RI are combined with RII (Weiss G. and Massagué J. (1996) EMBO J 15:276-289). RII-RI interaction would give rise to phosphorylation of RI and subsequent activation of its serine/threonine kinase which would phosphorylate to second messengers like the MADR2 proteins (Macías-Silva M et al., (1996) Cell 87:1215-1224).
- (1)

Role of TGF β 1 in hepatic differentiation and regeneration

30

The effects produced are different depending on the moment of development and on the type of cell.

- Enlargement of the extracellular matrix, on acting upon the liver stellate cells (Ito cells), the principal source of matrix proteins (Mustoe TA et al. (1987) Science 237:1333-1336).

35

REPLACEMENT SHEET

AMENDED SHEET

- Differentiation of the epithelial cells and hepatocytes (Florini JR et al. (1986) J. Biol. Chem. 261:16509-16513).
- Inhibition of cell growth during the process of liver regeneration. This effect is of great importance in the maintenance of cell rest *in vivo* (Kato Y et al. (1988) Proc. Natl. Acad. Sci. 85:9552-9556).
- Inhibition of endocytosis of the receptor of the epithelial growth factor (EGF) as has been observed in cultures of foetal rat hepatocytes (Noda M. and Rodan GA (1987) J. Cell Physiol. 133:426-437).

Role of TGF β 1 in hepatic fibrosis

TGF β 1 has been found to be associated with the processes of hepatic fibrosis (Czaja MJ et al. (1989) J. Cell Biol. 108:2477-2482; Annoni G. et al. (1992) J. Hepatol. 14:259-264) causing an increase in production of proteins of the extracellular matrix, by the liver stellate cells (lipocytes or Ito cells), of their receptors and inhibiting synthesis of the proteolytic enzymes that degrade the matrix (Ignatz RA and Massagué J. (1986) J. Biol. Chem. 261:4337-4345). In the liver, TGF β 1 induces the synthesis of collagen and fibronectin in the liver stellate cells (Weiner FR (1990) Hepatology 11:111-117). There is also auto-regulation by increasing its own synthesis, via induction of its mRNA.

TGF β 1 has also been found to be involved in increased synthesis of α 2-macroglobulin synthesized by the hepatocytes and the activated liver stellate cells. By binding to TGF β 1 and causing its inactivation (Bachem MG (1994) Ann NY Acad. Sci. 737:421-424), α 2-macroglobulin is said to eliminate TGF β 1 from the extracellular compartments.

Investigation of patients with chronic liver damage has shown that there is a correlation between expression of TGF β 1 and expression of the mRNA for the type I procollagen and the serum levels of type III peptide of procollagen (Castilla A. et al. (1991) N. Engl. J. Med. 324:933-940).

Patients with cirrhosis of the liver have a shorter than normal life expectancy owing to the complications that arise in the course of the disease, such as portal hypertension or hepatic failure.

Effect of TGF β 1 on the extracellular matrix

Interaction of TGF β 1 with the cell receptors causes:

- Activation of synthesis of procollagen, fibronectin (Ignatz RA et al. (1987) J. Biol. Chem. 262:6443-6446) and related proteins, including membrane proteins capable of interacting with the components of the extracellular matrix (Carter WG (1982) J. Biol. Chem. 257:13805-13815).
- Inhibition of the synthesis of proteolytic enzymes capable of degrading the matrix (Fukamizu H. and Grinnell F. (1990) Exp. Cell Res. 190:276-282).
- Stimulation of the synthesis of inhibitors of proteolytic enzymes (Fukamizu H. and Grinnell F. (1990) Exp. Cell Res. 190:276-282).

These effects lead to an increase in interactions of the cell with the extracellular matrix, which combined with greater reorganization of the proteins of which it is composed, gives rise to an increase in the total quantity of extracellular matrix (Roberts CJ et al. (1988) J. Biol. Chem. 263:4586-4592). These findings confirm that TGF β 1 is involved in cicatrization processes (Fukamizu H. and Grinnell F.

(1990) Exp. Cell Res. 190:276-282; Barnard JA et al.
(1990) Biochim. Biophys. Acta 1032:79-87).

Peptides as inhibitors of ligand-receptor interaction

5

There is the possibility of using small molecules, synthetic peptides, as analogues of molecules that are present in the body, with the aim of emulating their function. Studies conducted by LeSateur et al. demonstrate the possibility of using cyclized analogues of nerve growth factor (NGF), emulating the β turn region, permitting its binding to the receptor (LeSateur L. et al. (1996) Nature Biotechnology 14:1120-1122). It is also possible to use peptides as antagonists of these molecules, preventing the native factor interacting with its receptor by blocking mediated by the peptide (Lasarte JJ et al. (1994) J. Acquired Immune Deficiency Syndromes 7:129-134; LeSateur et al. (1995) J. Biol. Chem. 270:6564-6569).

20 Earlier studies had demonstrated the usefulness of synthetic peptides as inhibitors of ligand-receptor interaction even when the recognition epitope is not continuous (Daniels AJ et al. (1995) Mol. Pharmacol. 48:425-432). Other studies conducted with the type II

25 receptor of TGF β 1 and with fetuin, a glycoprotein in the group of type II receptors, have demonstrated the possibility of using cyclized peptides as inhibitors of the interaction of TGF β 1 with RII (Demetriou M. et al. (1996) J. Biol. Chem. 271:12755-12761). With this

30 cyclization it becomes possible to obtain peptides with a structure similar to that which could be obtained *in vivo*.

DETAILED DESCRIPTION OF THE INVENTION

For the reasons stated above, we consider that
5 peptides derived both from TGF β 1 and from its
receptors, or from proteins with capacity for binding
to TGF β 1, could be inhibitors of the action of TGF β 1.
We therefore decided to explore this possibility.

10 ***Selection of the peptides to be synthesized***

The peptides for synthesis were selected in
different ways depending on whether they were derived
from TGF β 1 or from its receptors.

15 In the case of the sequence of TGF β 1, peptides
were synthesized from 15 amino acids that include the
whole sequence of TGF β 1. Each peptide had 10 amino
acids in common with its two immediate neighbours.

In the case of the sequences of its receptors, the
20 peptides were chosen on the basis of software designed
in our laboratory. One of the computer programs
compares two amino acid sequences, with the aim of
predicting partially complementary regions. Other
programs were also used that were able to predict the
25 regions of the proteins that would be most exposed, on
the basis of the hydrophobicity and hydrophilicity of
the amino acids making up their sequence.

Synthesis of peptides

30

The peptides were synthesized by the solid phase
method (Merrifield (1963) J. Am. Chem. Soc. 85: 2149-
54), using fluorenylmethyloxycarbonyl (Fmoc) as a
temporary protecting group of the alpha-amino group
35 (Atherton et al. (1989) Journal of Chemical Society
Perkins Transactions 1: 538-546). For the synthesis of

small quantities of a large number of peptides, a multiple synthesizer was used, permitting the simultaneous synthesis of 96 peptides (Borrás-Cuesta et al. (1991) *Biologicals* 19: 187-190). The peptides were stored at -80°C in the solid state until used.

Purification of the peptides by HPLC

The synthesized peptides were analysed and purified by high-performance liquid chromatography (HPLC), using a Waters 600E-900 system (Millipore Corp., Bedford, USA).

A Waters Radial-Pak™ C₁₈ 300 Å 15 µm, 8x100mm column (Millipore Corp., Bedford, USA) was used for analysis of the peptides by analytical HPLC. The peptide was dissolved in a 0.1% solution of TFA in distilled water, to a maximum concentration of 1 mg/ml. The solution of peptide was injected (100 µl) into the column and was eluted in a water/acetonitrile gradient (Fig. 15) (Romil Ltd., Cambridge, USA) both with 0.1% TFA at a flow rate of 1 ml/min. The fractions that contained the peptide were detected by its absorbance at 220 nm and 280 nm (photodiode array detector, Waters 991, Millipore Corp., Bedford, USA).

A Waters Delta-Pak™ C₁₈ 300 Å 15 µm, 25x100mm column (Millipore Corp., Bedford, USA) was used for its purification. The peptide was dissolved and was injected (2 ml) under the same conditions as in the preceding case, employing the same gradient at a flow rate of 5 ml/min. The fraction that contained the pure peptide was collected in a flask.

IN VITRO TESTS. INVESTIGATION OF THE ACTIVITY OF THE
PEPTIDES

5 **Cell lines**

A line derived from mink pulmonary epithelium, MV-1-Lu, was used (CCL-64, American Type Cell Culture, Virginia, USA). The cells were grown in 162 cm² culture
10 flasks (Costar Corporation, Cambridge, USA) in a stove at 37°C and 5% CO₂, until subconfluence was attained. A complete medium was used: RPMI 1640 with L-glutamine (GibcoBRL, Life Technologies Ltd., Paisley, Scotland) supplemented with 5% of foetal calf serum (FCS,
15 Biological Industries, Kibbutz Beit Haemek, Israel), 10 mM HEPES (1M HEPES Buffer, Bio-Whittaker, Verviers, Belgium) and antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin).

20 **Test of inhibition of the growth of the MV-1-Lu cell line**

The MV-1-Lu cells grown as indicated above were removed from the bottom of the culture flasks using
25 5 ml of trypsin-EDTA (Biological Industries, Kibbutz Beit Haemek, Israel), resuspended in complete medium and centrifuged at 1500 rev/min for 8 minutes. After centrifugation the cells were resuspended in complete medium to a concentration of 50,000 cells/ml. For
30 conducting the test, 10 ml of the cell suspension were taken and dispensed in 96-well, flat-bottom culture plates (Costar Corporation, Cambridge, USA), adding 100 µl/well, and were incubated overnight at 37°C and 5% CO₂, which permits adhesion of the cells to the
35 bottom of the wells. At the end of this time, the peptides to be tested were added in RPMI, to a final

concentration of 200 µg/ml in the presence of a concentration of 200 pg/ml of TGFβ1 in RPMI (R&D Systems Europe Ltd., Abingdon, UK). The final concentration of FCS in the well was 2.5%. After 24 hours of incubation, 1 µCi of tritiated thymidine was added per well (25 Ci/mmol [methyl-³H]-thymidine, Amersham Life Science, Buckinghamshire, UK) with incubation for a further 12 hours (Grubeck-Loebenstein B. et al. (1989) J. Clin. Invest. 83:764-770; Brennan FM et al. (1990) Clin. Exp. Immunol. 81:278-285).

At the end of the incubation periods the cells were removed from the bottom of the wells with trypsin-EDTA and were collected using a manual harvester (Titertek cell harvester, Skatron Instruments Inc., Sterling, USA) which ruptures the cells, collecting the DNA in nitrocellulose filters (Filter MAT 11731, Skatron Instruments Inc., Sterling, USA) where it is fixed. The filters were placed individually in 5 ml polypropylene tubes to which 4 ml of scintillation fluid was added (Biogreen-11, Reactivos Scharlau S.A., Barcelona, Spain). The activity of each tube was quantified for 90 seconds in a β LKB scintillation counter (Beta plate system, LKB, Uppsala, Sweden).

25 Investigation of inhibition of binding of TGFβ1 to the cell receptors
Selective labelling of the cell receptors (affinity labelling)

30 The MV-1-Lu cells were removed from the culture flasks incubating them at 37°C for 10 minutes, with 10 ml of solution 1 (128 mM NaCl, 5 mM KCl, 25 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulphonate at pH 7.5, 5 mM glucose and 1 mM EDTA). The cells thus removed
35 were resuspended in solution 2 (128 Mm NaCl, 5 mM KCl, 50 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulphonate

at pH 7.5, 1.2 mM CaCl_2 , 1.2 mM MgSO_4 and 5 mg/ml BSA) and were collected by centrifugation at $1000 \times g$ for 5 minutes. After centrifugation the cells were resuspended in solution 2 at a concentration of 10^6 cells/ml.

From this cell suspension, 0.5 ml aliquots were made in 24-well plates (Greiner GmbH, Frickenhausen, Germany), the peptides were added, in 50 μl of a 0.8 mg/ml solution, then this was incubated for 2 hours at 4°C with stirring. Next, ^{125}I -TGF β 1 (2 μCi) was added to a final concentration of 277.2 pM (^{125}I -TGF β 1 human recombinant 800-2200Ci/mmol, Amersham Life Science, Buckinghamshire, UK) and this was incubated for a further two hours at 4°C with stirring.

After incubation, the cells were transferred to a centrifuge tube and were centrifuged cold at $12,000 \times g$ for 1 minute. They were then washed twice in cold solution 2 and were resuspended in 0.5 ml of cold solution 2, 5 μl of dimethyl sulphoxide (DMSO 99.5%, Sigma Chemical Co., St. Louis, USA) and disuccimidyl suberate (DSS, Pierce Chemical Co., Rockford, USA) giving a final concentration of 0.25 mM of DSS. Reaction was stopped at 15 minutes by dilution, centrifugation and washing with a solution containing 0.25M saccharose, 10 mM Tris and 1 mM EDTA at pH 7.4. The precipitate of cells was resuspended in 0.5 ml of Triton X-100 (Bio-Rad Laboratories, Hercules, USA) 1% v/v, 10 mM Tris at pH 7.0, 1 mM EDTA, 0.1 mM phenylmethylsulphonyl fluoride, 1 $\mu\text{g/ml}$ pepstatin and 1 $\mu\text{g/ml}$ leupeptin (Sigma Chemical Co., St. Louis, USA) and incubated for 40 minutes at 4°C . The fraction that is insoluble in detergent is separated by centrifugation at $12,000 \times g$ for 15 minutes. The fractions that are soluble in detergent (supernatant) and insoluble (precipitate) were frozen at -20°C .

(Massagué J. and Like B. (1985) J. Biol. Chem. 260:2636-2645).

5 ***Electrophoresis of proteins in sodium polyacrylamide dodecyl sulphate gel***

The fractions soluble and insoluble in detergent were used for analysis by electrophoresis in acrylamide/bisacrylamide gels at 7.5% for 5-6 hours at 10 220 volts.

The proteins were stained with a solution of (comassie brilliant blue® R250 (Serva Feinbiochemica GmbH, Heidelberg, Germany) in methanol (50%), acetic acid (10%) and distilled water, for 30 minutes. 15 Subsequent washings were effected with a solution of methanol (50%), acetic acid (10%) and distilled water for 15 minutes, in the first washing, and methanol (2.5%), acetic acid (0.5%) and distilled water, in the subsequent washings, until the background colour was 20 removed.

Flow cytometry

Inhibition of the binding of TGFβ1, mediated by 25 peptides, to the cell receptors was measured by the direct immunofluorescence method. An immunofluorescence kit was used for this (Fluorokine rh TGFβ-biotin, R&D Systems Europe Ltd., Abingdon, UK). This test is based on the capacity of biotinylated TGFβ1 to bind to the 30 cell receptors, in a specific manner, and the subsequent interaction of the biotin with fluorescein-labelled avidin, so that the signal intensity will depend on the quantity of TGFβ1 bound to the cell receptors.

35 The MV-1-Lu cells grown in 162 cm² flasks were removed using solution 1 (described previously) and

were resuspended in physiological saline for centrifugation at 500 x g for 5 minutes. After centrifugation, the cells were resuspended again in physiological saline at a concentration of 4x10⁶ cells/ml. 25 µl of the cell suspension was added to 12x75 mm borosilicate tubes, to which was added the peptide to be tested in 40 µl of RPMI 1640 medium, giving a final concentration of 0.42 µg/µl and 10 µl of biotinylated TGFβ1. As a control of specificity, 10 µl of a biotinylated reagent supplied with the kit was added, 10 µl of biotinylated TGFβ1 was added as a positive control and 20 µl of anti-TGFβ1 blocking antibody was added as a negative control. Physiological saline was added to all the controls until a total volume of 75 µl was reached. All the tubes were incubated for 1 hour at 4°C in darkness.

At the end of the incubation period, 10 µl of fluorescein-labelled avidin was added, incubating for 30 minutes at 4°C in darkness, after which 2 ml of a washing solution (RDF1) was added, followed by centrifugation at 500 x g for 6 minutes. The cell precipitate was resuspended in 0.2 ml of cold PBS for cytometry (FACScan, Becton Dickinson Immunocytometry Systems, California, USA). This method permits measurement of the fluorescence emitted by each cell when a laser beam is incident upon it, by means of a computer program (Lisys™ II, Becton Dickinson Immunocytometry Systems, California, USA). Fig. 16 shows a typical image from analysis by flow cytometry.

To obtain the data on inhibition of the binding of TGFβ1 to the receptors, the positive control of the test was used for delimiting the fields corresponding to the labelled cells, that have bound to the TGFβ1-biotin (M2) and to the unlabelled cells (M1). Once the fields had been delimited, the percentage of cells

located in each of them was calculated. The same was done with the data obtained when the peptide was incubated with TGF β 1-biotin or with the cells, depending on whether they were derived from the
5 receptors or the TGF β 1 respectively. With these data, the percentage inhibition of each peptide was calculated using the following formula: $100 - ((M2 \text{ Peptide} - M2 \text{ Negative}) \times 100 / (M2 \text{ Positive} - M2 \text{ Negative}))$.

10

EXPERIMENTS IN VIVO. EXPERIMENTAL MODEL OF FIBROSIS

Male white rats (albino Wistar strain) from simultaneous litters (5 weeks \pm 1.5 weeks) were used,
15 in order to obtain a group that was homogeneous in age and initial weight. Throughout the experiments, the animals were kept in conditions of constant temperature (22°C) with a 12-hour cycle of light and darkness. They had free access to water and food.

20 Hepatic cirrhosis (HC) was induced by inhalation of carbon tetrachloride for 11 weeks, twice per week (López Novoa JM et al. (1976) Patología IX:223-240; Camps J. et al. (1987) Gastroenterology 93:498-505). Exposure to CCl₄ was effected by bubbling compressed
25 air, at a flow rate of 3 litres/min, through a gas wash-bottle. One minute of exposure was used initially, increasing by one minute per week until 4 minutes was reached in the fourth week. CCl₄ was not administered during the fifth week, starting again at the sixth week
30 with an exposure of 5 minutes. This exposure time was maintained until week 11. 400 mg/l of phenobarbital (Luminal®, Bayer, Leverkusen, Germany) was added to the drinking water, from one week before starting exposure to CCl₄ and until the end of the experimental period.
35 Before starting the treatment, one week was left, in which they were not administered CCl₄. During treatment

they were administered a weekly dose of CCl_4 , as recorded (Fig. 2).

Distribution of the animals

5

The animals were divided into 4 groups before beginning the process of induction of hepatic cirrhosis.

- 10 *Healthy controls (Co)*: Animals that were not subjected to the fibrosis process.

- Treated healthy controls (Co+P144)*: Animals that were not subjected to the fibrosis process and that were
15 administered the peptide P144 during the last 3 weeks (coinciding in time with the treatment of the group of rats Tto_2).

- Cirrhotic controls 1 (Ci₁)*: Animals subjected to the
20 process of induction of cirrhosis by inhalation of CCl_4 twice per week. These animals were separated into 2 groups on reaching the fifth week:

- Cirrhotic controls 1 (Ci₁)*: Animals that continued
25 to be subjected to the process of induction of fibrosis up to week 11, without being administered the peptide P144. They were administered saline serum on alternate days, throughout the induction process (weeks 5 to 11).

30

- Treated cirrhotics 1 (Tto₁)*: Animals that were administered the peptide P144 derived from the sequence of the type III receptor, on alternate days, during the process of induction of fibrosis,
35 from week 5 to week 11.

Cirrhotic controls 2 (Ci₂): Animals that continued to be subjected to the process of induction of fibrosis without receiving the peptide P144 or saline serum. This group was subdivided into another two on reaching
5 week 11.

Cirrhotic controls 2 (Ci₂): Cirrhotic animals that were not subjected to any type of treatment, kept as controls. These animals received injections of
10 saline serum for 3 weeks (weeks 13 to 15).

Treated cirrhotics 2 (Tto₂): Cirrhotic animals that were treated with the peptide derived from the sequence of the type III receptor (P144), for 3
15 weeks (weeks 13 to 15).

Treatment of the animals

- 20 • *Group Tto₁:* These animals underwent treatment during the fibrosis process. Treatment with the peptide started in the fifth week (before exposure to CCl₄ for 5 minutes) and continued up to the end of the eleven weeks of the cirrhosis induction process.
- 25 • *Group Tto₂:* These animals underwent treatment after completion of the process of induction of cirrhosis (11 weeks). Treatment started one week after the last inhalation of CCl₄ and continued for 21 days.

Before starting the treatment and on its completion, blood was taken from all the animals that
30 had been treated with the peptide. The peptide was administered by subcutaneous injection in the abdominal zone at a dose of 70 µg/animal in 500 µl of physiological saline.

Sacrifice of the animals and dissection of the liver

On completion of treatment of the animals with the peptide, both in the model with rats and in that with
5 mice, the animals were sacrificed by decapitation, after taking blood from them from the retro-orbital plexus with a capillary.

This was followed immediately by dissection of the liver and collection of samples.

10 The samples were cut and placed in formol as fixing solution, for later histologic examination. Other fragments were placed in cryotubes, which were immersed in liquid nitrogen and then stored at -80°C.

15 ***Anatomopathologic evaluation of the liver***

Histologic examination was carried out on fragments of liver previously fixed in formol for at least 24 hours, after which they were placed in ethanol
20 (70%).

After dehydrating they were embedded in paraffin blocks. Successive sections 3 μm thick were prepared from the blocks obtained, using a Leitz rotary microtome and steel blades. Prior to staining the
25 sections were deparaffined in xylene (*AnalaR*, *BDH*, *Poole, UK*) for 15 minutes, after heating them at 60°C in a stove for 15 minutes, and they were hydrated by successive passes through alcohols of decreasing concentration 100%, 96%, 80% and 70% and finally in
30 water. The following stains were used:

Haematoxylin-eosin.

Masson's trichromic (Locquin M. and Langeron, (1985) in *Manual de Microscopía Ed. Labor S.A. Barcelona*): Uses a specific dye for collagen proteins (green light).

35 Sirius Red: A stain specific for collagen.

Confirmation of hepatic fibrosis: image analysis

For image analysis of the samples obtained, a light microscope was used (*Olympus BH-2, Tokyo, Japan*) connected to a video camera (*Sony DXP-950P, Sony Co., Tokyo, Japan*), with which the various fields of each preparation were photographed. Six fields were taken at random from each preparation stained with Sirius Red. The various images captured were analysed by means of a computer program (*Visilog 4.1.5, Noesis, Orsay, France*) which calculates the area of fibrosis and the total area of the preparation. From these data, a fibrosis index (area of fibrosis/total area) was calculated for each field. To be able to use this program it was necessary to modify image acquisition by using polarized light filters (*Olympus U-POT, Tokyo, Japan*) and green light filters (*Olympus IF550, Tokyo, Japan*) which made it possible to automate the process of sample analysis.

20

Detection of collagen in 14 μ m sections of paraffin-treated tissue

The 14 μ m sections that were used for this technique were obtained in the same way as the 3 μ m sections mentioned previously. These sections were subjected to a process of deparaffination for 12 hours in xylene. Once the paraffin had been eliminated, the samples were hydrated by passing them through different grades of alcohol 96%, 80%, 50%, completing the process in distilled water.

Once hydrated, they were subjected to a process of prestaining in a solution of 160 mg of Fast Green FCF (*Fluka Chemika-BioChemika, Buchs, Switzerland*) in 160 ml of saturated picric acid (*Merck, Darmstadt, Germany*) for 15 minutes in darkness. The samples were

- washed by immersion in water until they no longer coloured the wash water. Once the surplus dye was removed, the samples were stained for 30 minutes in darkness in a solution of 160 mg of *Direct Red 80* (Fluka Chemika-BioChemika Buchs, Switzerland) and 64 mg of *Fast Green*, both dyes in 160 ml of saturated picric acid. They were washed again until the surplus dye was removed, and then the samples were removed from the slides by scraping the sample off with a small spatula.
- The sections removed in this way were placed in separate tubes containing 3 ml of a solution of NaOH 0.1 N (*Quimón, Montplet&Esteban S.A., Barcelona, Spain*) and methanol (1:1). Aliquots were taken from the various tubes for reading in the spectrophotometer (*Lambda 2 UV/VIS spectrophotometer, Perkin-Elmer, Norwalk, USA*) at wavelengths of 540 nm and 630 nm using as blank an aliquot of the solution of NaOH 0.1 N and methanol (*López de León A. and Rojkind (1985) Histochem. Cytochem. 33:737-743; Gaudio E. et al. (1993) Int. J. Exp. Path. 74:463-469*).

In accordance with the works of Gaudio E. et al. (1993) *Int. J. Exp. Path. 74:463-469*, the following formulae were used for finding the quantities of collagen and total protein:

$$\text{mg collagen} = \frac{\text{absorbance at 540 nm} - \text{absorbance at 630 nm}}{37}$$

$$\text{mg collagen/mg total protein} = \frac{\text{mg collagen}}{\text{mg collagen} + \text{mg non-collagen proteins}}$$

$$\text{Non-collagen proteins} = \frac{\text{absorbance at 630 nm}}{3}$$

35 **Statistical analysis of the results**

The data obtained in the experiments *in vivo* were subjected to statistical analysis. Normality of the

quantitative variables was verified by the Shapiro-Wilks test.

As the data had not been adjusted to a normal distribution, non-parametric statistical analysis was undertaken. Comparison between groups was effected by means of Kruskal-Wallis H followed by comparison of Mann-Whitney U. The data were presented graphically by means of boxes, with representation of the median of the data (thick line inside each box), together with the interquartile range (height of the box), whereas the "whiskers" of each box represent the highest and lowest observations within a given interquartile range.

The association between variables was investigated using Fisher's exact test. Logistic regression was employed for investigating the independence of association of these variables.

A value of P equal to or less than 0.05 was regarded as significant.

All the statistical analyses were accomplished using the program SPSS for Windows V 6.1.3.

INHIBITION IN VITRO OF THE ACTIVITY OF TGF β 1

Test of inhibition of cell growth of the MV-1-Lu line

25

TGF β 1 is a cytokine that is able to inhibit the growth *in vitro* of the MV-1-Lu cell line (Grubeck-Loebenstein B. et al. (1989) J. Clin. Invest. 83:764-770; Brennan FM et al. (1990) Clin. Exp. Immunol. 81:278-285), therefore this line was used for testing the blocking effect of peptides on TGF β 1. After different combinations of media, cells and thymidine, we studied the effect of different concentrations of TGF β 1 on incorporation of [methyl- 3 H]thymidine by MV-1-Lu cells in culture, for determining the most

suitable conditions for the test. These conditions are shown in Fig. 3.

Once both the optimum concentration of MV-1-Lu cells (5000 cells/well) and the lowest concentration of TGF β 1 capable of producing inhibition of about 90% (200 pg/ml, Fig. 18) had been determined, the inhibitory effect of the synthetic peptides at a concentration of 200 μ g/ml was tested.

10

Inhibition in vitro of the activity of TGF β 1 by synthetic peptides

The synthetic peptides that are potentially inhibitors of TGF β 1 activity, selected as indicated above in the section: selection of the peptides to be synthesized (both those derived from proteins that bind to TGF β 1 and TGF β 1 itself) were tested using the MV-1-Lu cell line. The peptides were dissolved in buffered RPMI medium, free from foetal calf serum, and the following procedure was used:

The peptides belonging to the sequence of the receptor, or complementary to the peaks of hydrophilicity of TGF β 1, were incubated for 30 minutes in the presence of this cytokine and were then combined with the cell culture. The peptides derived from the sequence of TGF β 1 were added to the cell culture prior to addition of TGF β 1, since they interact with the receptors of the cell surface. These incubations were effected in 100 μ l of the same medium as was used for adding the cells. The active peptides permitted cell growth to a greater or lesser degree depending on its ability to inhibit TGF β 1.

Inhibition of TGF β 1 by means of peptides derived from TGF β 1

In a first stage, overlapping peptides derived
5 from TGF β 1 were synthesized. These peptides (Table 2)
were synthesized in the hope that some of them could
bind to the cell receptors, thus preventing the binding
of natural TGF β 1 to these receptors.

10 Table 2. Peptides derived from TGF β 1. The number of the
peptide is shown, together with its position in the
complete sequence, as well as its amino acid sequence.
For convenience of synthesis, all the peptides were
synthesized with an alanine added at the C-terminal end
15 which is not shown in the table.

Peptide	Sequence
P1 ₍₂₈₀₋₂₉₃₎	AlaLeuAspThrAsnTyrCysPheSerSerThrGluLysAsn
P2 ₍₂₈₄₋₂₉₇₎	AsnTyrCysSerSerThrGluLysAsnCysCysValArg
P3 ₍₂₈₈₋₃₀₁₎	SerSerThrGluLysAsnCysCysValArgGlnLeuTyrIle
P4 ₍₂₉₄₋₃₀₇₎	CysCysValArgGlnLeuTyrIleAspPheArgLysAspLeu
P5 ₍₂₉₈₋₃₁₁₎	GlnLeuTyrIleAspPheArgLysAspLeuGlyTrpLysTrp
P6 ₍₃₀₂₋₃₁₅₎	AspPheArgLysAspLeuGlyTrpLysTrpIleHisGluPro
P7 ₍₃₀₆₋₃₁₉₎	AspLeuGlyTrpLysTrpIleHisGluProLysGlyTyrHis
P8 ₍₃₀₈₋₃₂₁₎	GlyTrpLysTrpIleHisGluProLysGlyTyrHisAlaAsn
P9 ₍₃₁₂₋₃₂₅₎	IleHisGluProLysGlyTyrHisAlaAsnPheCysLeuGly
P10 ₍₃₁₆₋₃₂₉₎	LysGlyTyrHisAlaAsnPheCysLeuGlyProCysProTyr
P11 ₍₃₁₉₋₃₃₃₎	HisAlaAsnPheCysLeuGlyProCysProTyrIleTrpSerLeu
P12 ₍₃₂₂₋₃₃₅₎	PheCysLeuGlyProCysProTyrIleTrpSerLeuAspThr
P13 ₍₃₂₆₋₃₃₉₎	ProCysProTyrIleTrpSerLeuAspThrGlnTyrSerLys
P14 ₍₃₃₀₋₃₄₃₎	IleTrpSerLeuAspThrGlnTyrSerLysValLeuAlaLeu
P15 ₍₃₃₅₋₃₄₉₎	ThrGlnTyrSerLysValLeuAlaLeuTyrAsnGlnHisAsnPro
P16 ₍₃₃₆₋₃₄₉₎	GlnTyrSerLysValLeuAlaLeuTyrAsnGlnHisAsnPro
P17 ₍₃₄₀₋₃₅₃₎	ValLeuAlaLeuTyrAsnGlnHisAsnProGlyAlaSerAla
P18 ₍₃₄₃₋₃₅₈₎	LeuTyrAsnGlnHisAsnProGlyAlaSerAlaAlaProCysCys
P19 ₍₃₄₄₋₃₅₈₎	TyrAsnGlnHisAsnProGlyAlaSerAlaAlaProCysCys
P20 ₍₃₄₈₋₃₆₀₎	AsnProGlyAlaSerAlaAlaProCysCysValProGln
P21 ₍₃₅₀₋₃₆₃₎	GlyAlaSerAlaAlaProCysCysValProGlnAlaLeuGlu
P22 ₍₃₅₄₋₃₆₇₎	AlaProCysCysValProGlnAlaLeuGluProLeuProIle
P23 ₍₃₅₈₋₃₇₁₎	ValProGlnAlaLeuGluProLeuProIleValTyrTyrVal
P24 ₍₃₆₄₋₃₇₇₎	ProLeuProIleValTyrTyrValGlyArgLysProLysVal
P25 ₍₃₆₈₋₃₈₁₎	ValTyrTyrValGlyArgLysProLysValGluGlnLeuSer
P26 ₍₃₇₂₋₃₈₅₎	GlyArgLysProLysValGluGlnLeuSerAsnMetIleVal
P27 ₍₃₇₈₋₃₉₁₎	GluGlnLeuSerAsnMetIleValArgSerCysLysCysSer

5 Fig. 4 shows the inhibitory effect of the peptides in Table 6 on the activity of TGF β 1. Since TGF β 1 inhibits growth of the MV-1-Lu cells, inhibition of this cytokine by the peptides leads to re-establishment of growth of the MV-1-Lu cells.

As can be seen from Fig. 4, the peptide P12, derived from the sequence of TGF β 1, is the one that exhibits greater inhibitory activity of TGF β 1. For more detailed investigation of the inhibitory effect of peptide P12, an investigation was conducted into the effect of the concentration of the peptide on inhibition of the cytokine, which is described below.

Dose-response test of the inhibition of TGF β 1 by the peptide P12

The effect of the concentration of peptide P12 on inhibition of the activity of TGF β 1 was investigated. As this peptide was not readily soluble in the test medium, stock solutions or suspensions were prepared with a nominal concentration of peptide (that which would have been achieved if the peptide had dissolved completely) and aliquots were taken from these, and were filtered or even were used directly for the inhibition tests.

Fig. 5 examines the inhibitory effect of nominal concentrations of peptide, before and after filtration. It can be seen that peptide P12, with and without filtration, has practically the same activity.

Once the results had been obtained with peptide P12, it was decided to lengthen the peptide, both in the N-terminal and the C-terminal direction, and to investigate the effect on its activity. In addition, changes were made to its sequence to improve its solubility and study the importance of the two cysteines in its sequence on the inhibitory activity of TGF β 1. The peptides synthesized are stated in Table 3.

Table 3. Peptides derived from modification of peptide P12.

Peptide	Sequence
P12 ₍₃₂₂₋₃₃₃₎	PheCysLeuGlyProCysProTyrIleTrpSerLeuAspThr
P28 ₍₃₂₂₋₃₄₄₎	PheCysLeuGlyProCysProTyrIleTrpSerLeuAspThrGlnLysVal LeuAlaLeuTyr
P29 ₍₃₁₃₋₃₃₅₎	HisGluProLysGlyTyrHisAlaAsnPheCysLeuGlyProCysProTyr IleTrpSerLeuAspThr
P30	PheSerLeuGlyProCysProTyrIleTrpSerLeuAspThr
P31	PheCysLeuGlyProSerProTyrIleTrpSerLeuAspThr
P32	PheSerLeuGlyProSerProTyrIleTrpSerLeuAspThr
P33	PheCysLeuGlyProCysProTyrIleTrpSerAspAspAsp
P34	AspAspAspGlyProCysProTyrIleTrpSerLeuAspThr
P35	AspAspAspGlyProCysProTyrIleTrpSerAspAspAsp
P36	GlyProCysProTyrIleTrpSerAspAspAsp
P37	AspAspAspGlyProCysProTyrIleTrpSer
P38	AspGlyProCysProTyrIleTrpSerAsp

Fig. 6 shows the results of inhibition of TGFβ1 by the peptides in Table 3.

It can be seen from Fig. 6 that peptide P29 is active. This peptide includes the previously tested peptide P12 and has 9 extra amino acids towards the N-terminal end (Fig. 4). Investigations conducted by Quian SW et al. (1992) Proc. Natl. Acad. Sci. 89:6290-6294 and by Burmester JK et al. (1993) Proc. Natl. Acad. Sci. 90:8628-8632 using chimeric recombinant proteins identified a region of TGFβ1 that is necessary for the activity of this cytokine (amino acids 40 to 82 in the sequence of mature TGFβ1). It was speculated that peptide P29 (amino acids 34 to 56 in the sequence of mature TGFβ1), extending over a larger region than peptide P12 (amino acids 43 to 56), might acquire a three-dimensional structure more like the structure of the TGFβ1 in circulation. For this reason, peptide P29 was used for tests of binding to the cell receptors, based on affinity labelling.

Tests of inhibition of the binding of TGF β 1 to its receptors by peptide P29 (affinity labelling)

Peptide P29, derived from the sequence of TGF β 1,
5 was used in affinity labelling tests for verifying its capacity for inhibition of the binding of TGF β 1 to its cell receptors (Material and Methods).

Owing to the different activity of the batches of
125I-TGF β 1 employed, the concentrations of peptide used
10 in the tests were adjusted according to the concentration of the 125I-TGF β 1 batch used in each case. The results of these tests are shown in Figs. 7 and 8.

Further tests were carried out to find the minimum concentration required for blocking the binding of
15 125I-TGF β 1 to the cell receptors.

Inhibition of TGF β 1 by peptides derived from the sequence of the type III receptor of the rat

20 With the aim of finding new peptides that are inhibitors of the activity of TGF β 1, peptides derived from the type III receptor of the rat were synthesized. Some peptides were chosen on the basis of regions of their sequence that were predicted as complementary to
25 blocks of amino acids of the sequence of TGF β 1. It was hoped that these peptides would be capable of binding to free TGF β 1, sequestering it and preventing its binding to the cell receptors.

Other peptides were synthesized by overlapping 10 amino acids and covering part of the extracellular region of the type III receptor (amino acids 45 to 410). It has been described that a soluble type III receptor exists that corresponds to the extracellular region of the receptor, this region is cut from the
35 membrane and acts as a sequestrator of the TGF β 1 in

circulation (López Casillas F. et al. (1991) Cell 67:785-795). Later studies described two possible regions of binding to TGFβ1, one of which is located at the N-terminal end of the receptor (López-Casillas et al. (1994) J. Cell Biol. 124:557-568) and the other is located in the region closest to the membrane, towards the C-terminal end (Fukushima D. et al. (1993) J. Biol. Chem. 268:22710-22715; Pepin MC et al. (1995) FEBS Lett 377:368-372). For these reasons peptides of the extracellular region of this receptor were synthesized, on the supposition that these peptides might be capable of sequestering the circulating TGFβ1.

The peptides synthesized are shown in Table 4.

Table 4. Peptides derived from the type III receptor of the rat. The number of the peptide and its sequence are shown. P39 to P65 are peptides predicted as complementary to TGFβ1 and P66 to P138 are overlapping peptides covering the extracellular region of the receptor. For convenience of synthesis, all the peptides were synthesized with an alanine added at the C-terminal end which is not shown in the table.

Peptide	
P39 ⁽⁹¹⁻¹⁰²⁾	AsnProIleAlaSerValHisThrHisHisLysPro
P40 ⁽¹⁰⁴⁻¹¹⁵⁾	ValPheLeuLeuAsnSerProGlnProLeuValTrp
P41 ⁽¹⁰⁹⁻¹²⁰⁾	SerProGlnProLeuValTrpHisLeuLysThrGlu
P42 ⁽¹¹⁰⁻¹²¹⁾	ProGlnProLeuValTrpHisLeuLysThrGluArg
P43 ⁽¹³³⁻¹⁴⁴⁾	TrpAlaLeuAspAsnGlyTyrArgProValThrSer
P44 ⁽⁴²⁸⁻⁴³⁹⁾	ProIleValProSerValGlnLeuLeuProAspHis
P45 ⁽⁵⁵⁵⁻⁵⁶⁶⁾	GlyAspGluGlyGluThrAlaProLeuSerArgAla
P46 ⁽⁵⁶³⁻⁵⁷⁴⁾	LeuSerArgAlaGlyValValValPheAsnCysSer
P47 ⁽⁶⁰³⁻⁶¹⁴⁾	LeuPheLeuValProSerProGlyValPheSerVal
P48 ⁽⁶⁰⁵⁻⁶¹⁶⁾	LeuValProSerProGlyValPheSerValAlaGlu
P49 ⁽⁷⁰⁷⁻⁷¹⁸⁾	GluLeuThrLeuCysSerArgLysLysGlySerLeu
P50 ⁽⁷¹²⁻⁷²³⁾	SerArgLysLysGlySerLeuLysLeuProArgCys
P51 ⁽⁷¹⁷⁻⁷²⁸⁾	SerLeuLysLeuProArgCysValThrProAspAsp
P52 ⁽⁷²²⁻⁷³³⁾	ArgCysValThrProAspAspAlaCysThrSerLeu
P53 ⁽⁷²⁷⁻⁷³⁸⁾	AspAspAlaCysThrSerLeuAspAlaThrMetIle
P54 ⁽⁷³¹⁻⁷⁴²⁾	ThrSerLeuAspAlaThrMetIleTrpThrMetMet
P55 ⁽⁷³²⁻⁷⁴³⁾	SerLeuAspAlaThrMetIleTrpThrMetMetGln
P56 ⁽⁷³⁷⁻⁷⁴⁸⁾	MetIleTrpThrMetMetGlnAsnLysLysThrPhe
P57 ⁽⁷⁴²⁻⁷⁵²⁾	MetGlnAsnLysLysThrPheThrLysProLeuAla
P58 ⁽⁷⁴⁷⁻⁷⁵⁸⁾	ThrPheThrLysProLeuAlaValValLeuGlnVal
P59 ⁽⁷⁶¹⁻⁷⁷⁵⁾	LysGluAsnValProSerThrLysAspSerSerProIleProPro
P60 ⁽⁷⁶⁶⁻⁷⁸⁰⁾	SerThrLysAspSerSerProIleProProProProGlnIle
P61 ⁽⁷⁷¹⁻⁷⁸⁵⁾	SerProIleProProProProGlnIlePheHisGlyLeuAsp
P62 ⁽⁷⁷⁶⁻⁷⁹⁰⁾	ProProProGlnIlePheHisGlyLeuAspThrLeuThrValMet
P63 ⁽⁷⁸¹⁻⁷⁹⁵⁾	PheHisGlyLeuAspThrLeuThrValMetGlyIleAlaPheAla
P64 ⁽⁷⁸⁶⁻⁸⁰⁰⁾	ThrLeuThrValMetGlyIleAlaPheAlaPheValIleGly
P65 ⁽⁷⁹⁷⁻⁸⁰⁹⁾	LeuLeuThrGlyAlaLeuTrpTyrIleTyrSerHis
P66 ⁽⁸⁴⁵⁻⁸⁵⁹⁾	LeuMetGluSerPheThrValLeuSerGlyCysAlaSerArgGly
P67 ⁽⁸⁵⁰⁻⁸⁶⁴⁾	ThrValLeuSerGlyCysAlaSerArgGlyThrThrGlyLeuPro
P68 ⁽⁸⁵⁵⁻⁸⁶⁹⁾	CysAlaSerArgGlyThrThrGlyLeuProArgGluValHisVal
P69 ⁽⁸⁶⁰⁻⁸⁷⁴⁾	ThrThrGlyLeuProArgGluValHisValLeuAsnLeuArgSer
P70 ⁽⁸⁶⁵⁻⁸⁷⁹⁾	ArgGluValHisValLeuAsnLeuArgSerThrAspGlnGlyPro
P71 ⁽⁸⁷⁰⁻⁸⁸⁴⁾	LeuAsnLeuArgSerThrAspGlnGlyProGlyGlnArgGlnArg
P72 ⁽⁸⁷⁵⁻⁸⁸⁹⁾	ThrAspGlnGlyProGlyGlnArgGlnArgGluValThrLeuHis
P73 ⁽⁸⁸⁰⁻⁸⁹⁴⁾	GlyGlnArgGlnArgGluValThrLeuHisLeuAsnProIleAla

P74⁽⁸⁵⁻⁹⁹⁾ GluValThrLeuHisLeuAsnProIleAlaSerValHisThrHis
P75⁽⁹⁰⁻¹⁰⁴⁾ LeuAsnProIleAlaSerValHisThrHisHisLysProIleVal
P76⁽⁹⁵⁻¹⁰⁹⁾ SerValHisThrHisHisLysProIleValPheLeuLeuAsnSer
P77⁽¹⁰⁰⁻¹¹⁴⁾ HisLysProIleValPheLeuLeuAsnSerProGlnProLeuVal
P78⁽¹⁰⁵⁻¹¹⁹⁾ PheLeuLeuAsnSerProGlnProLeuValTrpHisLeuLysThr
P79⁽¹¹⁰⁻¹²⁴⁾ ProGlnProLeuValTrpHisLeuLysThrGluArgLeuAlaAla
P80⁽¹¹⁵⁻¹²⁹⁾ TrpHisLeuLysThrGluArgLeuAlaAlaGlyValProArgLeu
P81⁽¹²⁰⁻¹³⁴⁾ ArgLeuAlaAlaGlyValProArgLeuPheLeuValSerGluGly
P82⁽¹²⁵⁻¹³⁹⁾ GlyValProArgLeuPheLeuValSerGluGlySerValValGln
P83⁽¹³⁰⁻¹⁴⁴⁾ PheLeuValSerGluGlySerValValGlnPheProSerGlyAsn
P84⁽¹³⁵⁻¹⁴⁹⁾ GlySerValValGlnPheProSerGlyAsnPheSerLeuThrAla
P85⁽¹⁴⁰⁻¹⁵⁴⁾ PheProSerGlyAsnPheSerLeuThrAlaGluThrGluGluArg
P86⁽¹⁴⁵⁻¹⁵⁹⁾ PheSerLeuThrAlaGluThrGluGluArgAsnPheProGlnGlu
P87⁽¹⁵⁰⁻¹⁶⁴⁾ GluThrGluGluArgAsnPheProGlnGluAsnGluHisLeuVal
P88⁽¹⁵⁵⁻¹⁶⁹⁾ AsnPheProGlnGluAsnGluHisLeuValArgTrpAlaGlnLys
P89⁽¹⁶⁰⁻¹⁷⁴⁾ AsnGluHisLeuValArgTrpAlaGlnLysGluTyrGlyAlaVal
P90⁽¹⁶⁵⁻¹⁷⁹⁾ ArgTrpAlaGlnLysGluTyrGlyAlaValThrSerPheThrGlu
P91⁽¹⁷⁰⁻¹⁸⁴⁾ GluTyrGlyAlaValThrSerPheThrGluLeuLysIleAlaArg
P92⁽¹⁷⁵⁻¹⁸⁹⁾ ThrSerPheThrGluLeuLysIleAlaArgAsnIleTyrIleLys
P93⁽¹⁸⁰⁻¹⁹⁴⁾ LeuLysIleAlaArgAsnIleTyrIleLysValGlyGluAspGln
P94⁽¹⁸⁵⁻¹⁹⁹⁾ AsnIleTyrIleLysValGlyGluAspGlnValPheProProThr
P95⁽¹⁹⁰⁻²⁰¹⁾ ValGlyGluAspGlnValPheProProThrCysAsnIleGlyLys
P96⁽¹⁹⁵⁻²⁰⁹⁾ ValPheProProThrCysAsnIleGlyLysAsnPheLeuSerLeu
P97⁽²⁰⁰⁻²¹⁴⁾ CysAsnIleGlyLysAsnPheLeuSerLeuAsnTyrLeuAlaGlu
P98⁽²⁰⁵⁻²¹⁹⁾ AsnPheLeuSerLeuAsnTyrLeuAlaGluTyrLeuGlnProLys
P99⁽²¹⁰⁻²²⁴⁾ AsnTyrLeuAlaGluTyrLeuGlnProLysAlaAlaGluGlyCys
P100⁽²¹⁵⁻²²⁹⁾ TyrLeuGlnProLysAlaAlaGluGlyCysValLeuProSerGln
P101⁽²²⁰⁻²³⁴⁾ AlaAlaGluGlyCysValLeuProSerGlnProHisGluLysGlu
P102⁽²²⁵⁻²³⁹⁾ ValLeuProSerGlnProHisGluLysGluValHisIleIleGlu
P103⁽²³⁰⁻²⁴⁴⁾ ProHisGluLysGluValHisIleIleGluLeuIleThrProSer
P104⁽²³⁵⁻²⁴⁹⁾ ValHisIleIleGluLeuIleThrProSerSerAsnProTyrSer
P105⁽²⁴⁰⁻²⁵⁴⁾ LeuIleThrProSerSerAsnProTyrSerAlaPheGlnValAsp
P110⁽²⁶⁵⁻²⁷⁹⁾ AspProGluValValLysAsnLeuValLeuIleLeuLysCysLys
P111⁽²⁷⁰⁻²⁸⁴⁾ LysAsnLeuValLeuIleLeuLysCysLysLysSerValAsnTrp
P112⁽²⁷⁵⁻²⁸⁹⁾ IleLeuLysCysLysLysSerValAsnTrpValIleLysSerPhe
P113⁽²⁹⁰⁻²⁹⁴⁾ LysSerValAsnTrpValIleLysSerPheAspValLysGlyAsn
P114⁽²⁸⁵⁻²⁹⁹⁾ ValIleLysSerPheAspValLysGlyAsnLeuLysValIleAla
P115⁽²⁹⁰⁻³⁰⁴⁾ AspValLysGlyAsnLeuLysValIleAlaProAsnSerIleGly

P106₍₂₄₅₋₂₅₉₎ SerAsnProTyrSerAlaPheGlnValAspIleIleValAspIle
P107₍₂₅₀₋₂₆₄₎ AlaPheGlnValAspIleIleValAspIleArgProAlaGlnGlu
P108₍₂₅₅₋₂₆₉₎ IleIleValAspIleArgProAlaGlnGluAspProGluValVal
P109₍₂₆₀₋₂₇₄₎ ArgProAlaGlnGluAspProGluValValLysAsnLeuValLeu
P116₍₂₉₅₋₃₀₉₎ LeuLysValIleAlaProAsnSerIleGlyPheGlyLysGluSer
P117₍₃₀₀₋₃₁₄₎ ProAsnSerIleGlyPheGlyLysGluSerGluArgSerMetThr
P118₍₃₀₅₋₃₁₉₎ PheGlyLysGluSerGluArgSerMetThrMetThrLysLeuVal
P119₍₃₁₀₋₃₂₄₎ GluArgSerMetThrMetThrLysLeuValArgAspAspIlePro
P120₍₃₁₅₋₃₂₉₎ MetThrLysLeuValArgAspAspIleProSerThrGlnGluAsn
P121₍₃₂₀₋₃₃₄₎ ArgAspAspIleProSerThrGlnGluAsnLeuMetLysTrpAla
P122₍₃₂₅₋₃₃₉₎ SerThrGlnGluAsnLeuMetLysTrpAlaLeuAspAsnGlyTyr
P123₍₃₃₀₋₃₄₄₎ LeuMetLysTrpAlaLeuAspAsnGlyTyrArgProValThrSer
P124₍₃₃₅₋₃₄₉₎ LeuAspAsnGlyTyrArgProValThrSerTyrThrMetAlaPro
P125₍₃₄₀₋₃₅₄₎ ArgProValThrSerTyrThrMetAlaProValAlaAsnArgPhe
P126₍₃₄₅₋₃₅₉₎ TyrThrMetAlaProValAlaAsnArgPheHisLeuArgLeuGlu
P127₍₃₅₀₋₃₆₄₎ ValAlaAsnArgPheHisLeuArgLeuGluAsnAsnGluGluMet
P128₍₃₅₅₋₃₆₉₎ HisLeuArgLeuGluAsnAsnGluGluMetArgAspGluGluVal
P129₍₃₆₀₋₃₇₄₎ AsnAsnGluGluMetArgAspGluGluValHisThrIleProPro
P130₍₃₆₅₋₃₇₉₎ ArgAspGluGluValHisThrIleProProGluLeuArgIleLeu
P131₍₃₇₀₋₃₈₄₎ HisThrIleProProGluLeuArgIleLeuLeuAspProAspHis
P132₍₃₇₅₋₃₈₉₎ GluLeuArgIleLeuLeuAspProAspHisProProAlaLeuAsp
P133₍₃₈₀₋₃₉₄₎ LeuAspProAspHisProProAlaLeuAspAsnProLeuPhePro
P134₍₃₈₅₋₃₉₉₎ ProProAlaLeuAspAsnProLeuPheProGlyGluGlySerPro
P135₍₃₉₀₋₄₀₄₎ AsnProLeuPheProGlyGluGlySerProAsnGlyGlyLeuPro
P136₍₃₉₅₋₄₀₉₎ GlyGluGlySerProAsnGlyGlyLeuProPheProPheProAsp
P137₍₄₀₀₋₄₁₄₎ AsnGlyGlyLeuProPheProPheProAspIleProArgArgGly
P138₍₄₀₅₋₄₁₉₎ PheProPheProAspIleProArgArgGlyTrpLysGluGlyGlu

The peptides in Table 4 were tested for their capacity to block TGF β 1 in the model of inhibition of the MV-1-Lu cell line. Since TGF β 1 is able to inhibit the growth of this line, inhibition of TGF β 1 by the peptides would be able to re-establish cell growth. These tests are shown in Figs. 9 to 12.

As can be seen in Figs. 9 to 12, there are various peptides that are able to inhibit the growth of the MV-1-Lu cell line to a greater or lesser degree, but only peptide P54 is capable of inhibiting the activity of TGF β 1 almost completely. With the aim of conducting a more thorough investigation of this peptide, tests were carried out using different concentrations of peptide against a fixed concentration of TGF β 1 of 200 pg/ml.

Dose-response test of the inhibition of TGF β 1 by peptide P54

The effect of the concentration of peptide P54 on inhibition of the activity of TGF β 1 was investigated. In view of the low solubility of this peptide, stock solutions with nominal concentration of peptide were prepared, as was done in the case of peptide P12, and aliquots were taken from them, and filtered, or even used directly for the inhibition tests.

Fig. 13 examines the inhibitory effect of nominal concentrations of peptide, before and after filtration. It can be seen that there is no measurable inhibitory activity in the filtrate of peptide P54.

Having verified the capacity of peptide P54 to inhibit the activity of TGF β 1 in a manner that depends on the dose used, we proceeded to synthesize new peptides, taking as a basis the sequence of P54, with the aim of trying to improve the solubility and hence its activity at lower doses. Two peptides derived from

the human type III receptor were also synthesized. One of these peptides (P144) is equivalent to peptide P54. The other peptide (P145) is similar to peptide P106 of the type III receptor of the rat, which had also demonstrated activity. These new peptides are shown in Table 5.

Table 5. Peptides derived from modification of peptide P54 (peptides P139 to P143) and of the human type III receptor (peptides P144 and P145).

Peptide	Sequence	Derivation
P54 ⁽⁷³¹⁻⁷⁴²⁾	ThrSerLeuAspAlaThrMetIleTrpThrMetMet	Rat type III receptor
P139	ThrSerLeuAspAlaThrMetIleTrpAspAspAsp	
P140	AspAspAspAlaThrMetIleTrpThrMetMet	
P141	AspAlaThrMetIleTrpAsp	
P142	ThrSerLeuMetIleTrpThrMetMet	
P143	ThrSerLeuAspAlaThrThrMetMet	
P144 ⁽⁷²⁹⁻⁷⁴²⁾	ThrSerLeuAspAlaSerIleIleTrpAlaMetMet GlnAsn	Human type III receptor
P145 ⁽²⁴¹⁻²⁵⁴⁾	SerAsnProTyrSerAlaPheGlnValAspIleThr IleAsp	Human type III receptor

The test of activity of the peptides in Table 5 is shown in Fig. 14.

Dose-response test of inhibition of TGF β 1 by peptide P144

A dose-response test was carried out with peptide P144 derived from the sequence of the human type III receptor, with the aim of testing whether its activity was dependent on the concentration (Fig. 15). It can be seen that the activity of the peptide decreases with the decrease in the concentration of peptide used in the tests.

Tests of inhibition of the binding of TGF β 1 to its receptors by peptide P144 (affinity labelling)

Peptide P144 derived from the sequence of the human type III receptor was used in affinity labelling tests for verifying its ability to inhibit the binding of TGF β 1 to its cell receptors (Material and Methods).

Owing to the different activity of the batches of ^{125}I -TGF β 1 employed, the concentrations of peptide used in the tests were adjusted according to the concentration of the ^{125}I -TGF β 1 batch used in each case. The results of these tests are shown in Fig. 15.

After verifying inhibition of the binding of TGF β 1 to its cell receptors by peptide P144, a new test was conducted with the aim of titrating peptide P144. It was observed that the peptide lost its activity at a concentration of 2×10^5 times the molar concentration of ^{125}I -TGF β 1.

20 Inhibition of TGF β 1 by peptides derived from other proteins with ability to bind to TGF β 1 and predicted as complementary to TGF β 1

The peptides in Table 6, derived from proteins capable of binding to TGF β 1, were synthesized in this series.

Table 6. Peptides derived from various proteins capable of binding to TGF β 1 (type II receptor P146, fetuin P147 to P149, endoglin P150 to P154 and α 2-macroglobulin P155 to P179). The number of the peptide is shown, together with its position in the complete sequence, its amino acid sequence, and its origin. For convenience of synthesis, all the peptides were

synthesized with an alanine added at the C-terminal end which is not shown in the table.

Peptide	Sequence	Origin
P146 ⁽⁸⁴⁻¹⁰¹⁾	CysValAlaValTrpArgLysAsnAspGluAsnIleThr LeuGluThrValCys	Type II receptor
P147 ⁽¹¹²⁴⁻¹¹³²⁾	CysAspPheGlnLeuLeuLysLeuAspGlyLysPheSer ValValTyrAlaLysCys	Fetuin
P148 ⁽¹¹¹⁴⁻¹¹²²⁾	CysAspPheHisIleLeuLysGlnAspGlyGlnPheArg ValCysHisAlaGlnCys	Fetuin
P149 ⁽¹¹¹⁴⁻¹¹²²⁾	CysAspIleHisValLeuLysGlnAspGlyPheSerVal LeuPheThrLysCysAsp	Fetuin
P150 ⁽¹²⁴⁷⁻¹²⁶¹⁾	GluAlaValLeuIleLeuGlnGlyProProTyrValSer TriLeu	Endoglin
P151 ⁽¹²⁸⁹⁻¹³⁰³⁾	ValAsnLeuProAspThrArgGlnGlyLeuLeuGluGlu AlaArg	Endoglin
P152 ⁽¹⁴⁴⁵⁻¹⁴⁵⁹⁾	LeuAspSerLeuSerPheGlnLeuGlyLeuTyrLeuSer ProHis	Endoglin
P153 ⁽¹⁴⁸¹⁻¹⁴⁹⁵⁾	ProSerIleProGluLeuMetThrGlnLeuAspSerCys GlnLeu	Endoglin
P154 ⁽¹⁴⁷⁸⁻¹⁴⁹²⁾	MetSerProSerIleProGluLeuMetThrGlnLeuAsp SerCys	Endoglin
P155 ⁽¹¹¹⁻¹²⁴⁾	LeuLeuLeuLeuValLeuLeuProThrAspAlaSer	α -2-Macroglobulin
P156 ⁽¹³⁰⁻¹¹¹⁾	ProThrAspAlaSerValSerGlyLysProGlnTyr	α -2-Macroglobulin
P157 ⁽¹⁴⁴⁻¹³⁵⁾	ThrGluLysGlyCysValLeuLeuSerTyrLeuAsn	α -2-Macroglobulin
P158 ⁽¹¹⁶⁶⁻¹¹⁷⁷⁾	TyrIleGlnAspProLysGlyAsnArgIleAlaGln	α -2-Macroglobulin
P158 ⁽¹¹⁶⁶⁻¹¹⁷⁷⁾	TyrIleGlnAspProLysGlyAsnArgIleAlaGln	α -2-Macroglobulin
P159 ⁽¹¹⁹²⁻¹²⁰¹⁾	PheProLeuSerSerGluProPheGlnGlySerTyr	α -2-Macroglobulin
P160 ⁽¹²⁴⁷⁻¹²⁵⁸⁾	AsnValSerValCysGlyLeuTyrThrTyrGlyLys	α -2-Macroglobulin
P161 ⁽¹²⁴⁸⁻¹²⁵⁹⁾	ValSerValCysGlyLeuTyrThrTyrGlyLysPro	α -2-Macroglobulin
P162 ⁽¹²⁵⁰⁻¹²⁶¹⁾	ValCysGlyLeuTyrThrTyrGlyLysProValPro	α -2-Macroglobulin
P163 ⁽¹²⁶⁷⁻¹²⁷⁸⁾	SerIleCysArgLysTyrSerAspAlaSerAspCys	α -2-Macroglobulin
P164 ⁽¹⁴⁶³⁻¹⁴⁸⁰⁾	ProCysGlyHisThrGlnThrValGlnAlaHisTyr	α -2-Macroglobulin
P165 ⁽¹⁵³⁴⁻¹⁵⁶⁵⁾	AspSerAlaLysTyrAspValGluAsnCysLeuAla	α -2-Macroglobulin
P167 ⁽¹⁷⁵⁰⁻¹⁸⁰²⁾	GlnProPhePheValGluLeuThrMetProTyrSer	α -2-Macroglobulin
P168 ⁽¹²¹⁷⁻¹²³⁸⁾	GlnLeuGluAlaSerProAlaPheLeuAlaValPro	α -2-Macroglobulin
P169 ⁽¹⁸¹⁵⁻¹⁸³⁶⁾	SerValGlnLeuGluAlaSerProAlaPheLeuAla	α -2-Macroglobulin
P170 ⁽¹⁸⁷⁶⁻¹⁸⁹¹⁾	AlaLeuGluSerGlnGluLeuCysGlyThrGluVal	α -2-Macroglobulin
P171 ⁽¹¹⁰⁹²⁻¹⁰¹²⁾	LysSerLysIleGlyTyrLeuAsnThrGlyTyr	α -2-Macroglobulin

P172 ₍₁₀₈₅₋₁₀₁₄₎	IleGlyTyrLeuAsnThrGlyTyrGlnArgGlnLeu	α-2-Macroglobulin
P173 ₍₁₀₆₂₋₁₀₇₇₎	LysArgLysGluValLeuLysSerLeuAsnGluGlu	α-2-Macroglobulin
P174 ₍₁₁₃₉₋₁₂₀₄₎	ValGlyHisPheTyrGluProGlnAlaProSerAla	α-2-Macroglobulin
P175 ₍₁₂₀₉₋₁₂₂₆₎	ThrSerTyrValLeuLeuAlaTyrLeuThrGlnAla	α-2-Macroglobulin
P176 ₍₁₂₁₁₋₁₂₂₂₎	TyrValLeuLeuAlaTyrLeuThrAlaGlnProAla	α-2-Macroglobulin
P177 ₍₁₂₃₆₋₁₂₆₇₎	ValAlaLeuHisAlaLeuSerLysTyrGlyAlaAla	α-2-Macroglobulin
P178 ₍₁₂₃₂₋₁₂₄₃₎	TyrGlyArgAsnGlnGlyAsnThrTrpLeuThrAla	α-2-Macroglobulin
P179 ₍₁₂₃₄₋₁₂₄₅₎	ArgAsnGlnGlyAsnThrTrpLeuThrAlaPheVal	α-2-Macroglobulin

Figs. 17 and 18 show the inhibitory activity of the peptides derived from Table 10.

As can be seen in Figs. 17 and 18, only peptide P150 showed activity greater than 50%. However, peptides P146 and P149, which had been described as active by Demetriou M et al. (1996) J. Biol. Chem. 271:12755-12761, were not found to be active under the conditions employed for this test.

Measurement by flow cytometry of the inhibitory effect of synthetic peptides on the binding of TGFβ1 to its cell receptors

Peptides derived from previous syntheses, both those that were synthesized from the sequence of TGFβ1 and those from the type III receptor, were used for measuring, by flow cytometry, their capacity to inhibit the binding of TGFβ1 to the cell receptors. In these tests the cells are incubated with the peptide before adding TGFβ1-biotin, which will be detected using avidin-FITC (Material and Methods). Then the fluorescence emitted by the avidin-FITC is measured: this will be directly proportional to the quantity of TGFβ1 bound to the cells and inversely proportional to the activity of the peptide. The results obtained with the most relevant peptides are shown in Fig. 19 and Table 7.

Table 7. Comparison of the inhibitory activity of TGF β 1, of some peptides, measured by bioassay of inhibition of growth of the MV-1-Lu¹ cells (peptide concentration 200 μ g/ml) with inhibition of the binding of TGF β 1 to its cell receptors measured using flow cytometry² (peptide concentration 420 μ g/ml).

Peptides	Bioassay (% inhibition) ¹	Cytometry (% inhibition) ²	Sequence
P29	77,6	92,34	HisGluProLysGlyTyrHis AlaAsnPheCysLeuGlyPro CysProTyrIleTrpSerLeu AspThr
P11	40	86	HisAlaAsnPheCysLeuGly ProCysProTyrIleTrpSer Leu
P12	96	77	PheCysLeuGlyProCysPro TyrIleTrpSerLeuAspThr
P18	18,2	6,5	LeuTyrAsnGlnHisAsnPro GlyAlaSerAlaAlaProCys Cys
P54	97	82,3	ThrSerLeuAspAlaThrMet IleTrpThrMetMet
P140	-1,7	69,8	AspAspAspAlaThrMetIle TrpThrMetMet
P142	70	72	ThrSerLeuMetIleTrpThr MetMet
P106	40	91	SerAsnProTyrSerAlaPhe GlnValAspIleIleValAsp Ile
P145	21	74,35	SerAsnProTyrSerAlaPhe GlnValAspIleThrIleAsp
P144	88	80	ThrSerLeuAspAlaSerIle IleTrpAlaMetMetGlnAsn
P150	64	73	GluAlaValLeuIleLeuGln GlyProProTyrValSerTrp Leu
P152	45	68,4	LeuAspSerLeuSerPheGln LeuGlyLeuTyrLeuSerPro His

INHIBITION IN VIVO OF THE ACTIVITY OF TGF β 1

Peptide P144 derived from the sequence of the human type III receptor, which had proved active in the bioassays of inhibition of growth of the MV-1-Lu cell line, was used in the tests *in vivo* for studying its inhibitory effect in the induction of experimental cirrhosis with CCl₄, in a rat model.

Model of experimental cirrhosis in Wistar rats

In this model, hepatic cirrhosis is induced by inhalation of carbon tetrachloride, for 11 weeks, twice per week (López Novoa JM et al. (1976) Patología IX:223-240; Camps J. et al. (1987) Gastroenterology 93:498-505) as described in Material and Methods.

Peptide P144 was administered in accordance with two protocols:

1. Protocol 1: The peptide was administered on alternate days by the intraperitoneal route during the cirrhosis induction process (11 weeks). Figs. 20 and 21.
2. Protocol 2: The peptide was administered on alternate days by the intraperitoneal route for 3 weeks, once cirrhosis was established, i.e. at 12 weeks from the start of induction of cirrhosis. Figs. 22 and 23.

The production of collagen in both protocols was measured by two techniques:

Figs. 36 and 38 show total collagen production measured by staining liver sections (two per animal) with *Fast Green* and *Direct Red*, elution of the colour and reading in a spectrophotometer (Material and Methods) (López de León A. and Rojkind (1985) *Histochem. Cytochem.* 33:737-743; Gaudio E. et al. (1993) *Int. J. Exp. Path.* 74:463-469).

Figs. 21 and 23 show collagen production, measured by image analysis of liver sections stained with *Sirius Red*, using light microscopy (Material and Methods).

As can be seen in Fig. 20, significant differences are observed ($P < 0.05$) between the group of rats treated with peptide P144 (Tto_1) and the control group of cirrhotic rats (Cl_1) on investigating the ratio of collagen to total protein. In Fig. 37, the differences between the group of rats treated with peptide P144 (Tto_1) and the control group of cirrhotic rats (Cl_1) are

also significant ($P < 0.001$) when the area of fibrosis is investigated.

As can be seen in Figs. 22 and 23, which show the results for the rats treated once cirrhosis was established, the differences between the groups of rats treated with peptide P144 (Tto_2) and the cirrhotic rats without treatment (Ci_2) are not significant when using either of the two techniques for measuring fibrosis.

The two techniques employed for measuring collagen were compared using linear regression with the aim of verifying the randomness of selection of the fields for investigation in each preparation and hence the validity of the image analysis, Figs. 24 and 25.

As can be seen from Figs. 24 and 25, there is a correlation between the two techniques with $R > 0.85$ in both cases, which is highly significant ($F \leq 0.001$). This confirms that acquisition of the images for investigation was effected entirely randomly and hence confirms the validity of the data obtained by image analysis.

Figs. 26 and 27 show the images obtained by light microscopy from liver preparations stained with Sirius Red at a magnification of 10X obtained from livers of rats treated during the cirrhosis induction process (Ci_1 and Tto_1).

The images in Fig. 26 were obtained without employing any type of filter.

Fig. 27 shows the images once they had been modified for investigation using special software. These modifications consist of application of two filters, one of polarized light and the other of green light, for the purpose of improving the quality of the images and facilitating automated examination of them.

Figs. 26 and 27 reveal that there are differences between the images obtained from the cirrhotic rats (Ci_1) and those obtained from the rats treated with peptide P144 (Tto_1).

The differences in effectiveness between protocols 1 and 2 might be due to the fact that production of TGF β 1 might be much less once cirrhosis is induced (protocol 2) than during the process of induction of cirrhosis with CCl₄ (protocol 1), and might even be at normal levels, so that the effect of treatment with peptide P144 would be less pronounced in protocol 2 than in protocol 1.

When we compare the groups of untreated cirrhotic rats, at the end of the process of induction of cirrhosis (Ci₁) with the untreated cirrhotic rats at 4 weeks from the end of induction (Ci₂), we find that there are significant differences ($P = 0.016$) between the two groups (Fig. 28), which would indicate that there is partial regression of cirrhosis when the cirrhotizing agent is removed, an observation that has been published by various authors (Szende-B et al. (1992) In Vivo 6:355-361; Columbano A (1996) Carcinogenesis 17:395-400).

These differences in effectiveness between the two protocols might also be due to the protocol itself, since the animals of protocol 2 are only treated for 3 weeks on alternate days, whereas the animals of protocol 1 are treated for a longer period of time (7 weeks, also on alternate days).

The results obtained demonstrate that it is possible to inhibit TGF β 1 both *in vitro* and *in vivo* by means of synthetic peptides derived from different proteins. In future it would be of great interest to try to increase the biological activity of these peptides. This might be accomplished by systematically replacing each of the amino acids of their sequences by the other 19. Once the peptide with greater activity was achieved it would be necessary to prepare mimotopes (McConnell-SJ (1994) Gene 151:115-118; Steward-MW (1995) J. Virol. 69:7668-7673) thereof with the aim of

increasing the average life of the inhibitory agent in the organism.

DESCRIPTION OF THE FIGURES

5

Fig. 1. Inhibition of binding of TGF β 1 to the MV-1-Lu cells by peptide P144, measured by flow cytometry. A, image obtained on examining the cells incubated with biotinylated TGF β 1 and developed with avidin-FITC. B, image obtained on examining the cells incubated with avidin-FITC without prior addition of TGF β 1. C, image obtained on examining the cells incubated with TGF β 1 previously incubated with peptide P144 at a concentration of 0.42 μ g/ μ l, and developed with avidin-FITC. The fluorescence emitted is shown on the abscissa, while the ordinate shows the number of cells for each value of fluorescence. The fields corresponding to the cells labelled with TGF β 1-biotin and avidin-FITC (M2) and to the unlabelled cells (M1) are also shown.

10

15

20

Fig. 2. Schematic representation of the process of cirrhosis by CCl₄. Black arrows indicate when two weekly doses of CCl₄ were administered to the rats, and black dashed arrows show when there was one weekly dose. The grey arrows indicate administration of peptide P144. A: Healthy controls; B: Healthy controls + P144, B₁: with peptide 70 μ g/day; C: Cirrhotic; C₁ with saline; C₂ with peptide 70 μ g/day; D: Cirrhotic with CCl₄ + phenobarbital; D₁ plus saline; D₂ plus peptide 70 μ g/day.

25

30

Fig. 3. Effect of TGF β 1 on growth of MV-1-Lu cells. The cells are cultivated at a density of 5000 cells/well at

the concentrations of TGF β 1 indicated, pg/ml. Abscissa: TGF β 1 concentration (pg/ml); Ordinate: c.p.m.

Fig. 4. Percentage inhibition of TGF β 1 (200 pg/ml) by peptides from TGF β 1. All the peptides were tested at a concentration of 200 μ g/ml. Inhibition of TGF β 1 of 100% corresponds to the growth of MV-1-Lu cells that is obtained in the absence of TGF β 1.

Fig. 5. Percentage inhibition of the activity of TGF β 1 (200 pg/ml) in the presence of various nominal concentrations of peptide P12, filtered (\blacklozenge) and unfiltered (\bullet).

Fig. 6. Percentage inhibition of TGF β 1 (200 pg/ml) by peptides from TGF β 1. All the peptides were tested at a concentration of 200 μ g/ml. Inhibition of TGF β 1 of 100% corresponds to the growth of MV-1-Lu cells that is obtained in the absence of TGF β 1.

Fig. 7. Autoradiograph of an affinity labelling test of the receptors of TGF β 1. Lane C1: effect of incubation of the cells with a concentration of 0.16 μ M of 125 I-TGF β 1 which corresponds to an activity of 0.3 μ Ci (positive control). Lane C2: effect of preincubation of the cells with a concentration of non-radioactive TGF β 1 10 times greater than that of 125 I-TGF β 1 (negative control). Lane C3: preincubation was effected with peptide P29 at a concentration 10^6 times greater than the molar concentration of 125 I-TGF β 1. It can be seen that there is inhibition of the binding of 125 I-TGF β 1 to the type I, II and III cell receptors both by peptide P29 and by non-radioactive TGF β 1.

Fig. 8. Autoradiograph of an affinity labelling test of the receptors of TGF β 1. Lanes C1 to C6: effect of preincubation of the MV-1-Lu cells, with different concentrations of peptide P29 (10^6 , 8×10^5 , 6×10^5 , 4×10^5 , 2×10^5 and 10^5 times the molar concentration of ^{125}I -TGF β 1 respectively), prior to addition of ^{125}I -TGF β 1. Lane C7: effect of preincubation of the MV-1-Lu cells with unlabelled TGF β 1 (10^2 times the molar concentration of ^{125}I -TGF β 1) prior to addition of ^{125}I -TGF β 1 (negative control). Lane C8: effect of incubation of the MV-1-Lu cells with a concentration of $0.42 \mu\text{M}$ of ^{125}I -TGF β 1, corresponding to an activity of $0.4 \mu\text{Ci}$, without prior preincubation (positive control).

Fig. 9. Percentage inhibition of TGF β 1 (200 pg/ml) by receptor peptides predicted as complementary to regions of TGF β 1. All the peptides were tested at a concentration of $200 \mu\text{g/ml}$. Inhibition of TGF β 1 of 100% corresponds to the growth of MV-1-Lu cells that is obtained in the absence of TGF β 1.

Fig. 10. Percentage inhibition of TGF β 1 (200 pg/ml) by overlapping peptides derived from the extracellular region of the type III receptor. All the peptides were tested at a concentration of $200 \mu\text{g/ml}$. Inhibition of TGF β 1 of 100% corresponds to the growth of MV-1-Lu cells that is obtained in the absence of TGF β 1.

Fig. 11. Percentage inhibition of TGF β 1 (200 pg/ml) by overlapping peptides derived from the extracellular region of the type III receptor. All the peptides were tested at a concentration of $200 \mu\text{g/ml}$. Inhibition of TGF β 1 of 100% corresponds to the growth of MV-1-Lu cells that is obtained in the absence of TGF β 1.

Fig. 12. Percentage inhibition of TGF β 1 (200 pg/ml) by overlapping peptides derived from the extracellular region of the type III receptor. All the peptides were
5 tested at a concentration of 200 μ g/ml. Inhibition of TGF β 1 of 100% corresponds to the growth of MV-1-Lu cells that is obtained in the absence of TGF β 1.

Fig. 13. Percentage inhibition of the activity of TGF β 1
10 (200 pg/ml) in the presence of different nominal concentrations of peptide P54, filtered (◆) and unfiltered (●).

Fig. 14. Percentage inhibition of TGF β 1 (200 pg/ml) by
15 receptor peptides derived from modification of peptide P54 (P139 to P143) and of the peptides derived from the human type III receptor (P144 and P145). All the peptides were tested at a concentration of 200 μ g/ml. Inhibition of TGF β 1 of 100% corresponds to the growth of MV-1-Lu cells that is obtained in the absence of TGF β 1.

20 Fig. 15. Percentage inhibition of the activity of TGF β 1 (200 pg/ml) in the presence of different nominal concentrations of peptide P144 without filtration.

25 Fig. 16. Autoradiograph of an affinity labelling test of the receptors of TGF β 1. Lane C1: preincubation was effected with peptide P144 at a concentration 10^6 times greater than the molar concentration of 125 I-TGF β 1. Lanes C2 and C3: effect of preincubation of the cells
30 with a concentration of non-radioactive TGF β 1 10 times greater than that of 125 I-TGF β 1 (negative control). Lanes C4 and C5: effect of incubation of the cells with a concentration of 0.1 μ M of 125 I-TGF β 1 that corresponds to an activity of 0.2 μ Ci (positive control). It can be
35 seen that there is inhibition of the binding of 125 I-TGF β 1

to the cell receptors both by peptide P144 and by the non-radioactive TGF β 1.

Fig. 17. Percentage inhibition of TGF β 1 (200 pg/ml) by peptides derived from human type II receptor (P146), from fetuin (P147 to P149) and from endoglin (P150 to P154). All the peptides were tested at a concentration of 200 μ g/ml. Inhibition of TGF β 1 of 100% corresponds to the growth of MV-1-Lu cells that is obtained in the absence of TGF β 1.

Fig. 18. Percentage inhibition of TGF β 1 (200 pg/ml) by peptides derived from α 2-macroglobulin. All the peptides were tested at a concentration of 200 μ g/ml. Inhibition of TGF β 1 of 100% corresponds to the growth of MV-1-Lu cells that is obtained in the absence of TGF β 1.

Fig. 19. Percentage inhibition of the binding of TGF β 1 to MV-1-Lu cells by various synthetic peptides. Inhibition was investigated by measuring the percentage of labelled cells (emit fluorescence) and unlabelled cells (do not emit fluorescence) for each peptide (Material and Methods).

Fig. 20. Effect of administration of peptide P144 on collagen synthesis during experimental cirrhosis induction with CCl₄. The ratio of collagen to total protein is shown on the ordinate. The abscissa shows the various groups of rats: Co= healthy rats; Co+P144= healthy rats treated with peptide P144; Tto₁= rats subjected to induction of cirrhosis with CCl₄ and administered peptide P144 on alternate days during this period and Ci₁= rats subjected to induction of cirrhosis with CCl₄ for 11 weeks and not treated with peptide P144.

Fig. 21. Effect of administration of peptide P144 on collagen synthesis during experimental cirrhosis induction with CCl_4 . The ordinate shows the ratio of the area of fibrosis to the total area in tissue preparations stained with Sirius Red. The abscissa shows the various groups of rats: Co= healthy rats; Co+P144= healthy rats treated with the peptide; Tto₁= rats subjected to induction of cirrhosis with CCl_4 and administered peptide P144 on alternate days during this period and Ci₁= rats subjected to induction of cirrhosis with CCl_4 for 11 weeks and not treated with peptide P144.

Fig. 22. Effect of administration of peptide P144 on collagen synthesis once cirrhosis has been induced with CCl_4 . The ordinate shows the ratio of collagen to total protein. The abscissa shows the various groups of rats: Co= healthy rats; Co+P144= healthy rats treated with the peptide; Tto₂= rats subjected to induction of cirrhosis with CCl_4 and administered peptide P144 on alternate days at the end of this period and Ci₂= rats subjected to induction of cirrhosis with CCl_4 for 11 weeks and not treated with peptide P144.

Fig. 23. Effect of administration of peptide P144 on collagen synthesis once cirrhosis has been induced with CCl_4 . The ordinate shows the ratio of the area of fibrosis to the total area in tissue preparations. The abscissa shows the various groups of rats: Co= healthy rats; Co+P144= healthy rats treated with the peptide; Tto₂= rats subjected to induction of cirrhosis with CCl_4 and administered peptide P144 on alternate days at the end of this period and Ci₂= rats subjected to induction of cirrhosis with CCl_4 for 11 weeks and not treated with peptide P144.

Fig. 24. Comparison of the data on quantity of collagen and area of fibrosis, obtained by the two techniques employed. The abscissa shows the values of the ratio of the area of fibrosis to the total area, obtained by image analysis. The ordinate shows the values of the ratio of μg of collagen to mg of total protein, obtained by spectrophotometric analysis of liver sections stained with Direct Red and Fast Green. R^2 is shown. ($F \leq 0.001$).

Fig. 25. Comparison of the data on quantity of collagen and area of fibrosis, obtained by the two techniques employed for examining the samples at the end of protocol 2. The abscissa shows the values of the ratio of the area of fibrosis to the total area, obtained by image analysis. The ordinate shows the values of the ratio of μg of collagen to mg of total protein, obtained by spectrophotometric analysis of liver sections stained with Direct Red and Fast Green. R^2 is shown. ($F \leq 0.001$).

Fig. 26. Images that are representative of the 24 fields obtained by light microscopy (10X) from rat liver preparations stained with Sirius Red. Cirrhotic rats (Ci_1) at the end of induction of cirrhosis with CCl_4 and cirrhotic rats treated (Tto_1) with peptide P144 during induction of cirrhosis with CCl_4 . Different fields were taken from preparations obtained from each animal (R = rat and C = field).

Fig. 27. Images that are representative of the 24 fields obtained by light microscopy (10X) from rat liver preparations stained with Sirius Red. Cirrhotic rats (Ci_1) at the end of induction of cirrhosis with CCl_4 and cirrhotic rats treated (Tto_1) with peptide P144

during induction of cirrhosis with CCl_4 . Different fields were taken from the preparations obtained from each animal (R= rat and C= field). Polarized light and a green filter were used in order to show up the collagen fibres.

Fig. 28. Comparison between the two groups of untreated cirrhotic rats. Ci_1 are cirrhotic rats at the end of the 12 weeks of induction of cirrhosis with CCl_4 , Ci_2 are cirrhotic rats at 4 weeks from the end of the process of induction of cirrhosis. $P = 0.016$. Ordinate: Area of fibrosis/Total area.

- 48 -

CLAIMS

- 1.- Peptides that are antagonists of the binding of TGFβ1 to its receptors in the body, characterized by being
5 synthetic peptides with sequences having ≤ 15 amino acids that are identical or similar to those of natural TGFβ1 and/or its receptors.
- 2.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 3.
- 10 3.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 4.
- 4.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 5.
- 5.- Active peptide according to Claim 1, characterized in
15 that it has the amino acid sequence SEQ ID NO: 6.
- 6.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 7.
- 7.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 8.
- 20 8.- Active peptide according to Claim 1, characterized in that it has the amino acid sequence SEQ ID NO: 9.
- 9.- Mimotopes of any of the active peptides of Claims 1 to 8, characterized in that they display an antagonistic effect similar to them, but a longer average life in the
25 body than the latter.
- 10.- Method of using at least one of the active peptides of Claims 1 to 8 and/or at least one of their mimotopes for manufacturing a composition for application in liver diseases.
- 30 11.- Method of using at least one DNA that codes for at least one of the active peptides of Claims 1 to 8 for manufacturing a composition for application in liver

REPLACEMENT SHEET

AMENDED SHEET

- 49 -

diseases that optionally includes at least one of the mimotopes of the said active peptides.

12.- Method of using at least one recombinant expression system that codes for at least one of the active peptides
5 of Claims 1 to 8 for manufacturing a composition for application in liver diseases that optionally includes at least one of the mimotopes of the said active peptides.

13.- Method according to Claim 12, characterized in that the recombinant system is a defective adenovirus.

10 14.- Method according to Claim 12, characterized in that the recombinant system is a plasmid.

15.- Method according to Claims 11 to 14 for application to hepatic fibrosis.

REPLACEMENT SHEET

AMENDED SHEET

ABSTRACT

"TGF β 1-INHIBITOR PEPTIDES"

Antagonistic synthetic peptides, obtained from TGF β 1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.

U013446-9

1/28






FIGURE 1




FIGURE 2

U013446-9

3/28





FIGURE 3

U013446-9

4/28

**FIGURE 4**

U013446-9

5/28




FIGURE 5

U013446-9

6/28




FIGURE 6

U013446-9

7/28




FIGURE 7

U013446-9

8/28




FIGURE 8

U013446-9

9/28




FIGURE 9

09/831253

U013446-9

10/28




FIGURE 10

U013446-9

11/28




FIGURE 11

09/831253

U013446-9

12/28




FIGURE 12

U013446-9

13/28




FIGURE 13

U013446-9

14/28




FIGURE 14

U013446-9

15/28




FIGURE 15

16/28



U013446-9

17/28




FIGURE 17

U013446-9

18/28




FIGURE 18

U013446-9

19/28




FIGURE 19

U013446-9

20/28




FIGURE 20

U013446-9

21/28




FIGURE 21

U013446-9

22/28




FIGURE 22




FIGURE 23

U013446-9

24/28




FIGURE 24

U013446-9

25/28




FIGURE 25




FIGURE 26

U013446-9

27/28


 Ci_1) Tto_1)

FIGURE 27




FIGURE 28

Optional Customer No. Bar Code



00140

PATENT TRADEMARK OFFICE

COMBINED DECLARATION AND POWER OF ATTORNEY

(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is of the following type:

(check one applicable item below)

- ☐ original.
☐ design.

NOTE: With the exception of a supplemental oath or declaration submitted in a reissue, a supplemental oath or declaration is not treated as an amendment under 37 CFR 1.312 (Amendments after allowance). M.P.E.P. Section 714.16, 7th Ed.

- ☐ supplemental.

NOTE: If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application, do not check next item; check appropriate one of last three items.

- ☒ national stage of PCT.

NOTE: If one of the following 3 items apply, then complete and also attach **ADDED PAGES FOR DIVISIONAL, CONTINUATION OR C-I-P**.

NOTE: See 37 C.F.R. Section 1.63(d) (continued prosecution application) for use of a prior nonprovisional application declaration in the continuation or divisional application being filed on behalf of the same or fewer of the inventors named in the prior application.

- ☐ divisional.
☐ continuation.

NOTE: Where an application discloses and claims subject matter not disclosed in the prior application, or a continuation or divisional application names an inventor not named in the prior application, a continuation-in-part application must be filed under 37 C.F.R. Section 1.53(b) (application filing requirements-nonprovisional application).

- ☐ continuation-in-part (C-I-P).

INVENTORSHIP IDENTIFICATION

WARNING: *If the inventors are each not the inventors of all the claims, an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.*

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor (*if only one name is listed below*) or an original, first and joint inventor (*if plural names are listed below*) of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

TGF-1-INHIBITOR PEPTIDES

SPECIFICATION IDENTIFICATION

The specification of which:

(complete (a), (b), or (c))

(a) ☐ is attached hereto.

NOTE: *"The following combinations of information supplied in an oath or declaration filed on the application filing date with a specification are acceptable as minimums for identifying a specification and compliance with any one of the items below will be accepted as complying with the identification requirement of 37 C.F.R. Section 1.63:*

"(1) name of inventor(s), and reference to an attached specification which is both attached to the oath or declaration at the time of execution and submitted with the oath or declaration on filing;

"(2) name of inventor(s), and attorney docket number which was on the specification as filed; or

"(3) name of inventor(s), and title which was on the specification as filed."

Notice of July 13, 1995 (1177 O.G. 60).

(b) ☐ was filed on _____, ☐ as Application No. _____
☐ and was amended on _____ (if applicable).

NOTE: *Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 C.F.R. Section 1.67.*

NOTE: *"The following combinations of information supplied in an oath or declaration filed after the filing date are acceptable as minimums for identifying a specification and compliance with any one of the items below will be accepted as complying with the identification requirement of 37 C.F.R. Section 1.63:*

- (A) application number (consisting of the series code and the serial number, e.g., 08/123,456);
 - (B) serial number and filing date;
 - (C) attorney docket number which was on the specification as filed;
 - (D) title which was on the specification as filed and reference to an attached specification which is both attached to the oath or declaration at the time of execution and submitted with the oath or declaration; or
 - (E) title which was on the specification as filed and accompanied by a cover letter accurately identifying the application for which it was intended by either the application number (consisting of the series code and the serial number, e.g., 08/123,456), or serial number and filing date. Absent any statement(s) to the contrary, it will be presumed that the application filed in the PTO is the application which the inventor(s) executed by signing the oath or declaration.
- M.P.E.P. Section 601.01(a), 7th ed.*

- (c) ☐ was described and claimed in PCT International Application No. PCT/ES99/00375 filed on 22.11.1999 and as amended under PCT Article 19 on _____ (if any).

SUPPLEMENTAL DECLARATION (37 C.F.R. Section 1.67(b))

(complete the following where a supplemental declaration is being submitted)

☐ I hereby declare that the subject matter of the

☐ attached amendment

☐ amendment filed on _____.

was part of my/our invention and was invented before the filing date of the original application, above identified, for such invention.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56,

(also check the following items, if desired)

☐ and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and

☐ in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 C.F.R. Section 1.98.

PRIORITY CLAIM (35 U.S.C. Section 119(a)-(d))

NOTE: "The claim to priority need be in no special form and may be made by the attorney or agent if the foreign application is referred to in the oath or declaration as required by Section 1.63. The claim for priority and the certified copy of the foreign application specified in 35 U.S.C. Section 119(b) must be filed in the case of an interference (Section 1.630), when necessary to overcome the date of a reference relied upon by the examiner, when specifically required by the examiner, and in all other situations, before the patent is granted. If the claim for priority or the certified copy of the foreign application is filed after the date the issue fee is paid, it must be accompanied by a petition requesting entry and by the fee set forth in Section 1.17(f). If the certified copy is not in the English language, a translation need not be filed except in the case of interference; or when necessary to overcome the date of a reference relied upon by the examiner; or when specifically required by the examiner, in which event an English language translation must be filed together with a statement that the translation of the certified copy is accurate." 37 C.F.R. Section 1.55(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) ☐ no such applications have been filed.
(e) ☒ such applications have been filed as follows.

NOTE: Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

**PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION
AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. SECTION 119(a)-(d)**

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING DAY, MONTH, YEAR	PRIORITY CLAIMED UNDER 35 USC 119
SPAIN	P9802465	24 November 1998	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. Section 119(e))

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER
_____/_____
_____/_____
_____/_____

FILING DATE

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)
UNDER 35 U.S.C. SECTION 120

- ☐ The claim for the benefit of any such applications are set forth in the attached
ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY
FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN-PART (C-I-P)
APPLICATION.

**ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

NOTE: If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage, or (2) a continuation, divisional, or continuation-in-part, then also complete ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR C-I-P APPLICATION for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. Section 120.

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

(list name and registration number)

JOSEPH H. HANDELMAN, 26179

RICHARD P. BERG, 28145

JOHN RICHARDS, 31053

JULIAN H. COHEN, 20302

RICHARD J. STREIT, 25765

WILLIAM R. EVANS 25858

PETER D. GALLOWAY, 27885

JANET I. CORD, 33778

IAN C. BAILLIE, 24090

CLIFFORD J. MASS, 30086

THOMAS F. PETERSON, 24790

CYNTHIA R. MILLER, 34678

(Check the following item, if applicable)

- ☐ I hereby appoint the practitioner(s) associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.
- ☐ Attached, as part of this declaration and power of attorney, is the authorization of the above-named practitioner(s) to accept and follow instructions from my representative(s).

NOTE: "Special care should be taken in continuation or divisional applications to ensure that any change of correspondence address in a prior application is reflected in the continuation or divisional application. For example, where a copy of the oath or declaration from the prior application is submitted for a continuation or divisional application filed under 37 CFR 1.53(b) and the copy of the oath or declaration from the prior application designates an old correspondence address, the Office may not recognize, in the continuation or divisional application, the change of correspondence address made during the prosecution of the prior application. Applicant is required to identify the change of correspondence address in the continuation or divisional application to ensure that communications from the Office are mailed to the current correspondence address. 37 CFR 1.63(d)(4)." Section 601.03, M.P.E.P., 7th Ed

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO:

(Name and telephone number)

Ladas & Parry

26 West 61st Street

New York, N.Y. 10023

(complete the following if applicable)

Since this filing is a [] continuation [] divisional there is attached hereto a Change of Correspondence Address so that there will be no question as to where the PTO should direct all correspondence.

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

NOTE: Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other document.

NOTE: Each inventor must be identified by full name, including the family name, and at least one given name without abbreviation together with any other given name or initial, and by his/her residence, post office address and country of citizenship. 37 C.F.R. Section 1.63(a)(3).

NOTE: Inventors may execute separate declarations/oaths provided each declaration/oath sets forth all the inventors. Section 1.63(a)(3) requires that a declaration/oath, inter alia, identify each inventor and prohibits the execution of separate declarations/oaths which each sets forth only the name of the executing inventor. 62 Fed. Reg. 53,131, 53,142, October 10, 1997.

Full name of sole or first inventor

100
Ignacio José (Given Name) (Middle Initial or Name) EZQUERRO SAENZ (Family (Or Last Name))
Inventor's signature Ignacio José Ezquerro Saenz
Date 17-05-01 Country of Citizenship Spain
Residence Travesía Monasterio de Velate, 2 - 3ªA, Pamplona, Spain ESX
Post Office Address Same as above

Full name of second joint inventor, if any

200
Juan José (Given Name) (Middle Initial or Name) LASARTE SAGASTIBELZA (Family (Or Last Name))
Inventor's signature Juan José Lasarte Sagastibelza
Date 17-05-01 Country of Citizenship Spain
Residence Avda. de Guipúzcoa, 24-3º, Berriozar, Spain ESX
Post Office Address Same as above

Full name of third joint inventor, if any

300
Jesús (Given Name) (Middle Initial or Name) PRIETO VALTUEÑA (Family (Or Last Name))
Inventor's signature Jesus M. Prieto Valtueña
Date 17-05-01 Country of Citizenship Spain
Residence Tudela, 22-4º, Pamplona, Spain ESX
Post Office Address Same as above

(check proper box(es) for any of the following added page(s)
that form a part of this declaration)

☒ **Signature** for fourth and subsequent joint inventors. *Number of pages added* _____

* * *

☐ **Signature** by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor. *Number of pages added* _____

* * *

☐ **Signature** for inventor who refuses to sign or cannot be reached by person authorized under 37 C.F.R. Section 1.47. *Number of pages added* _____

* * *

☐ Added page for **signature** by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 C.F.R. Section 1.47)

* * *

☐ Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.

☐ Number of pages added _____

* * *

☐ Authorization of practitioner(s) to accept and follow instructions from representative.

(If no further pages form a part of this Declaration,
then end this Declaration with this page and check the following item)

☐ This declaration ends with this page.

Practitioner's Docket No. _____

**ADDED PAGE TO COMBINED DECLARATION AND POWER OF
ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS**

Full name of fourth joint inventor, if any

Francisco

(Given Name)

(Middle Initial or Name)

BORRAS CUESTA

Family (Or Last Name)

Inventor's signature

Francisco Borras Cuesta

Date

17 May 2008

Country of Citizenship

Spain

Residence **Montecampamento, 37-3^aA, Mendillorri, Pamplona, Spain**

ESX

Post Office Address **Same as above**

Full name of fifth joint inventor, if any

(Given Name)

(Middle Initial or Name)

Family (Or Last Name)

Inventor's signature

Date

Country of Citizenship

Residence

Post Office Address

Full name of sixth joint inventor, if any

(Given Name)

(Middle Initial or Name)

Family (Or Last Name)

Inventor's signature

Date

Country of Citizenship

Residence

Post Office Address

- 1 -

SEQUENCE LISTING

<110> Instituto Científico y Tecnológico de Navarra (ICTN) *

<120> TGFβ1-inhibitor peptides

<160> 10

<210> SEQ ID NO: 1

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from TGFβ1, position 319-333

<400> His Ala Asn Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp

5

10

Ser Leu

15

<210> SEQ ID NO: 2

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from TGFβ1, position 322-335

<400> Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu Asp

5

10

Thr

<210> SEQ ID NO: 3

<211> 12

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Deduced as complementary to TGFβ1, position 731-742

<400> Thr Ser Leu Asp Ala Thr Met Ile Trp Thr Met Met

5

10

<210> SEQ ID NO: 4

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Overlapping with the extracellular region of the rat
type III receptor, position 245-259

<400> Ser Asn Pro Tyr Ser Ala Phe Gln Val Asp Ile Ile Val

5

10

Asp Ile

15

<210> SEQ ID NO: 5

<211> 9

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Modification P54 deduced as complementary to TGFβ1,
position 731-742

<400> Thr Ser Leu Met Ile Trp Thr Met Met

5

<210> SEQ ID NO: 6

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from the modified human type III receptor,
position 729-742

<400> Thr Ser Leu Asp Ala Ser Ile Ile Trp Ala Met Met Gln

5

10

Asn

<210> SEQ ID NO: 7

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from the modified human type III receptor,
position 241-254

<400> Ser Asn Pro Tyr Ser Ala Phe Gln Val Asp Ile Thr Ile

5

10

Asp

<210> SEQ ID NO: 8

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Position 247-261 of endoglin

<400> Glu Ala Val Leu Ile Leu Gln Gly Pro Pro Tyr Val Ser

5

10

Trp Leu

15

<210> SEQ ID NO: 9

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Position 445-459 of endoglin

<400> Leu Asp Ser Leu Ser Phe Gln Leu Gly Leu Tyr Leu Ser

5

10

Pro His

15

<210> SEQ ID NO: 10

<211> 23

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Modification P12, position 322-335 of TGFβ1

<400> His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly

5

10

Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr

15

20